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ABSTRACT 
Identification of the role of T cells and their interaction with other cell types remains a major 
challenge to our understanding of the pathogenesis of rheumatoid arthritis. In this study we 
have investigated the regulation of the response of T cells infiltrating the rheumatoid joint to 
IL-6. Furthermore we have investigated the level of T cell activation in the early stages of 
rheumatoid arthritis. 
Interleukin-6 is an important regulator of T cell differentiation and survival. It exerts its 
biological function by either directly binding to the complete IL-6 receptor consisting of 
CD126 CD130 or via transsignaling, when sIL6R-IL6 complexes bind to CD130. This study 
addresses the expression and regulation of these receptor components on the T cells 
infiltrating the rheumatoid joint. While compared to blood T cells, CD126 expression was 
found at low levels on synovial fluid and tissue T cells, expression of CD130 on synovial 
tissue T cells was comparable to that of blood T cells, with lower levels in synovial fluid T 
cells, both at protein and mRNA level. When exposed to sIL6R-IL6 complexes, tissue 
derived T cells responded with a higher level of STAT3 phosphorylation compared to cells 
incubated with IL-6, suggestive of transsignaling. High CD130 expression was demonstrable 
in T cells in the perivascular cuff area. Among a range of cytokines tested, IL-6 reduced 
CD126 and CD130 expression while IL-10, which is expressed at high levels in the 
perivascular infiltrate, induced expression of CD130. Taken together these data suggest that 
the inflammatory microenvironment maintains responsiveness to IL-6 transsignalling by 
cytokine driven CD130 expression on CD4 positive T cells. 
To address the question whether the role of T cells changes during the course of progression 
of RA, we analysed the expression of T cells activation markers on synovial fluid and 
peripheral blood T cells from patients at the very early stage of disease (within 3 months of 
disease onset) compared to patients with established or self resolving arthritis. Expression of 
CD69, CD71 and HLA-DR was upregulated on synovial fluid T cells compared to peripheral 
blood but there were no differences between the different groups of patients. Furthermore, we 
quantified the proportion of T cells expressing the invariant TCR Vα24Jα18 in synovial fluid 
and blood of the same groups of patients. We found a lower frequency of iNKT cells in the 
synovial fluid of very early arthritis patients compared to other patients. While this is a 
preliminary result, it suggests that there may be a role for these cells in the regulation of 
disease susceptibility.  
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  Chapter 1. 
 INTRODUCTION                      
1.1 The immune system 
The immune system is a complex defense system that has evolved to defend the body against 
a wide variety of pathogenic microorganisms and cancerous cells. It comprises the organs of 
the primary and secondary lymphatic system, specialized cells and soluble factors. All of 
these components of the immune system act in a coordinated fashion to achieve its function: 
to defend the body. 
It is able to discriminate between foreign and self in order to only attack and destroy invading 
pathogens or altered self. If this discrimination fails and the immune system directs its 
effector function to the host’s own cells and tissues, autoimmune diseases develop.  
We can divide this complex system into innate and adaptive responses. These are, however, 
not independent of each other and interact at multiple levels to ensure rapid and effective 
removal of pathogens. 
An innate immune response is triggered by recognition of patterns characteristic for 
pathogens by a limited number of receptors and soluble factors.  This phenomenon is known 
as pattern recognition. Examples are Toll-like receptors (TLR) recognizing bacterial and viral 
structures such as lipopolysaccharide and proteoglycans.  The innate immune system acts 
through four mechanisms: anatomical and physiological barriers, phagocytosis and 
inflammation. Physical barriers prevent the entry of microbes into the body; a very good 
example of a physical barrier is the skin. Other physical barriers include body secretions such 
as tears which can wash away invading pathogens, normal flora which competes for nutrients 
with invading microorganisms in mucous membranes and structures such as cilia which 
propel microorganisms that have been entrapped by mucus in the respiratory tract. 
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Physiological barriers that prevent pathogen invasion as part of the innate immune system 
include temperature and pH not suitable for microorganism survival. Soluble components of 
the innate immune system comprise factors such as lysozyme, interferons and complement. 
The complement system includes a set of proteins that once activated, attacks bacterial cell 
walls and facilitates pathogen clearance. Activated complement factors also alert cells of the 
innate and adaptive immune response to a site of infection.  Interferons are secreted by virally 
infected cells and trigger antiviral effects in neighboring cells to limit the spread of infection. 
Lyzosome is capable of breaking the peptidoglycan layer of the bacterial cell wall. It is 
present in body secretions such as mucus or tears.  
Inflammation is a complex sequence of events that follows a challenge of the body by 
irritation, injury, or infection. It is characterized by the following symptoms: Redness, Heat, 
Swelling, Pain and loss of function of the inflamed tissue. Inflammation will be described in 
more detail in section 1.4. 
The adaptive immune system is a more evolutionarily advanced branch of the immune system 
that recognizes a large range of different antigens specifically. It is characterized by antigenic 
specificity, diversity, memory and self/nonself recognition. Antigen specificity allows the 
immune system to distinguish between different antigenic challenges and react appropriately; 
it also allows the immune system to discriminate between self and non-self antigens. Once the 
adaptive immune system recognizes a foreign antigen and mounts a response it will retain 
memory of this particular antigen, often conferring the host life-long immunity to it. The 
adaptive immune system requires the collaboration between lymphocytes and antigen 
presenting cells to function. Lymphocytes can be subdivided into B and T cells. B cells 
express a surface bound immunoglobulin that can bind to native foreign antigen. When a 
mature B cells encounters the antigen, recognized by the surface immunoglobulins with a 
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high affinity it divides rapidly and the daughter cells will differentiate into plasma or B 
memory cells. A proportion of the activated B cells will undergo isotype subclass switching 
and hypermutation of the variable region genes to generate high affinity antibodies with a 
range of effector functions. Eventually, Plasma cells will secrete antibodies that bind to the 
triggering antigen; causing its clearance by phagocytic cells, complement activation, 
neutralization, and agglutination of pathogens.  Memory B cells stay in the body conferring 
long-term immunity to this particular antigen. In case of a subsequent encounter with the 
same antigen, memory B cells are much more efficient at proliferating and secreting high 
affinity IgG antibodies to defend the host. T cells are characterized by expression of the T cell 
receptor on their surface. This allows them to recognize antigens presented by an APC. Under 
a strictly controlled set of circumstances  the T cells becomes activated and reacts by secreting 
cytokines that will activate or regulate other cells of the immune system or by differentiating 
into cytotoxic T   Lymphocytes (CTLs) that will kill self altered cells (1)   
1.2. T cells 
Precursors of T lymphocytes are generated in the bone marrow, from where they migrate to 
the thymus, where they undergo further maturation steps. During maturation in the thymus T 
cells begin to express T Cell Receptors (TCR) on their surface. This receptor allows them to 
bind to antigen. The TCR is unique to each T cell clone and unlike B cells it does not 
recognize antigen on its own. The TCR recognizes antigen bound to a MHC molecule on the 
surface of an Antigen Presenting Cell (APC). Following stimulation a mature T cell will 
proliferate and differentiate, giving rise to memory T cells and effector T cells.  
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Figure 1. Antigen presentation by an APC to a T cell via TCR/MHC molecule 
interaction. The CD80/86 CD28 interaction shown here is an example of one of a large number of 
costimulatory/adhesion molecule interaction. 
1.2.1. T cell development, positive and negative selection 
T cell precursors travel from the bone marrow to the thymus where they will undergo a series 
of changes that will lead to development of mature T cells. The thymus is divided into 
subcapsular region, thymic cortex, corticomedullary junction and medulla. As thymocytes 
mature into T cells they travel across the different regions of the thymus. Thymocytes enter 
the thymus through endothelial venules and migrate to the subcapsular region where they will 
undergo rearrangement of their TCR genes. In the cortex thymocytes interact with cortical 
epithelial cells, at this point thymocytes are double-positive expressing CD4 and CD8 
4 
 
molecules as well as and αβTCR. If the thymocyte is able to recognize an MHC class I or 
class II molecule expressed by cortical epithelial cells it will receive a maturation and survival 
signal. Thymocytes that recognize MHC class I molecules lose the expression of CD4 and 
maintains CD8 expression, while thymocytes recognizing MHC class II molecules loose CD8 
expression becoming CD4 single positive thymocytes. Thymocytes unable to recognize MHC 
molecules die by apoptosis and thymocytes that recognize self peptide antigens presented by 
MCH class I or II molecules with high affinity also receive a pro-apoptotic signal and die to 
avoid the development of self-reacting T cells in a process known as central tolerance. The 
cells that survive the selection process migrate to the medulla where the remaining single 
positive CD4 or CD8 naïve T cells leave the thymus directly joining the bloodstream or via 
the lymphatic system (2) 
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 Figure 2. Positive and negative selection process in the thymus. Modified 
from: http://www.cartage.org.lb/en/themes/sciences/LifeScience/GeneralBiology/Immunology/Immun
ityInfection/CellActivation/TCellMaturation/TCellMaturation.htm 
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From a functional point of view T cells can be divided into T helper cells (Th) and cytotoxic 
T cells (Tc).  In general, Th cells express CD4 molecule on their surface and bind to antigen 
presented by MHC class II molecules expressed by APC such as B cells or dendritic cells. On 
the other hand, Tc express CD8 on their surface and only recognize antigen in the context of 
MHC Class I which is expressed by virtually all nucleated cells (2).  
When a naïve T cell encounters antigen, a primary response is initiated. Once the TCR 
encounters antigen, CD28 binds to CD80 and CD86 expressed by the APC and this triggers a 
co-stimulatory signal which supports proliferation and survival. There are other co-
stimulatory molecules but CD28 interaction with CD80 and CD86 is critical for T cells 
activation; without CD28 TCR engagement results in anergy. T cells divide repeatedly, giving 
rise to an expanded antigen specific T cell clone. In the case of Tc cells, following antigen 
recognition on the surface of a dendritic cell, the CD8 + T cells will evolved into CTL which 
have the ability to kill virally infected cells or self altered cells. When Th cells encounter 
antigen, they also proliferate and produce cytokines, but they can also be further polarized to 
form several functional subpopulations. Among these, Th1 cells predominantly secrete IL-2, 
IFN-γ, and TNF-β. Th2 cells secrete IL-4, IL-5, IL-6 and IL-10. Th1 cells are responsible for 
cell-mediated functions such as activation of macrophages, whereas Th2 cells stimulate B 
cells to switch to IgE production. Th17 cells are a newly identified subtype of T cells. They 
are defined by their ability to produce IL-17(3), additionally Th17 cells can produce  IL-21,  
TNFα, Lymphotoxin-β, IL-26 and IL-22.  Th17 cells are also characterized by the expression 
of chemokine receptor CCR6 and its ligand CCL20 (4,5). These cells play a role fighting 
extra-cellular pathogens such as bacteria or fungi (6). The differentiation of T cells into Th17 
cells is driven by IL-6 and TGF-β, further contributing factors are IL-1 and TNFα reviewed in 
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(7). Here, STAT3 is a key transcription factor as STAT3 deficiency results in the inability of 
T cells to differentiate into Th17 cells (8).  
1.2.2 T regs 
Regulatory T cells or Tregs are a relatively new T cell subtype with a specific role in 
regulating the immune response to protect the host from autoimmune disease. Tregs represent 
about 5-10% of the total CD4+ population in the bloodstream. They have been characterized 
by the expression of CD4, high levels of CD25 and expression of the transcription factor 
FoxP3 reviewed by (9). Depending on their origin, two different types of Tregs have been 
identified: natural Tregs and adaptive Tregs. Natural Tregs are generated in the thymus via 
TRC-MHC interaction whereas induced or adaptive Tregs are generated in secondary 
lymphoid organs and tissues (reviewed in (10). Adaptive Treg development was reported to 
require CTLA4 upregulation while natural Treg development may be CTLA4 independent 
(11). Treg produce TGF-β, IL-10, IL-12 and IL-35 (12). They are associated with 
maintenance of self-tolerance; this was established following experiments in which Tregs 
were depleted from mice. Treg depletion resulted in the development of widespread 
autoimmunity in these animals, affecting several organ systems, including the joints (13). 
Several additional studies have demonstrated the role of Tregs in preventing autoimmunity. 
NOD mice with partial Treg depletion have severe diabetes, which can be prevented by 
adoptive transfer of Tregs (14). In humans suffering from type I diabetes the number of Tregs 
seems to be comparable to healthy individuals, however, they  appear to be dysfunctional; a 
similar situation is observed in other autoimmune diseases such as rheumatoid arthritis, 
myasthenia gravis or multiple sclerosis (15,16).  
1.2.3  iNKT cells 
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iNKT cells are a subpopulation of  the T cell lineage that expresses a semi-invariant TCR and 
markers originally associated with NK cells, such as CD161. The semi-invariant TCR consists 
of a variable TCR Vβ11 chain in combination with an invariant TCR Vα24Jα18 (reviewed in 
(17)). In humans, iNKT cells represent about 0.2% of the total T cell population in peripheral 
blood (18). 40 to 60% of all iNKT cells are CD4 positive, most of the remaining are double 
negative (DN) (CD4 negative, CD8 negative) and a very small proportion are CD4 negative 
CD8 positive (19,20).  
iNKT cells recognize glycolipid antigens presented in the context of CD1d molecule by an 
antigen presenting cell, such as dendritic cells, B cells and macrophages (21-23). Several 
iNKT cell ligands have been described to date. The first iNKT cell ligand described is a 
component of the extract of marine sponge Agelas mauritianus, known as α-
galactosylceramide (α-GalCer) (24). Other iNKT cell ligands include bacterial antigens such 
as a-glucuronylceramide, found in Sphingomonas and a glycosphingolipid self Ligand 
isoglobotrihexosylceramide (iGb3) ( reviewed in (17)). 
Within minutes after activation, iNKT cells are able to secrete large amounts of cytokines 
(25). The iNKT subsets secrete different cytokines, CD4 positive iNKT cells can secrete Th1 
and Th2 cytokines, in contrast DN iNKT cells only secrete Th1-type cytokines (26-28). The 
ability of iNKT cells to secrete different combinations of cytokines confers on them the 
ability to polarize T cell responses towards Th-1 or Th-2 like responses. Therefore a critical 
immunomodulatory role has been proposed for iNKT cells (29). 
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Figure 3. iNKT cells recognizing a glycolipid antigen presented through a CD1d 
molecule. 
1.2.3.1 iNKT cell development 
iNKT cells develop in the thymus. Two models were originally proposed to explain iNKT 
cells development. The first one proposed the concept that iNKT cells come from a T cell 
precursor originally destined to become an iNKT cell. The second model suggests  that iNKT 
cells derive from a common T cell precursor but segregate from T cell development into 
iNKT cell development during positive selection where they recognize CD1d molecules by 
TCRs generated randomly (reviewed in (30)). Recent evidence favors the second model with 
iNKT cells developing from a common T cell precursor and segregating at the DP thymocyte 
stage, which is also the time when they express TCRαβ chain (reviewed in (31)). As Vα14-
Jα18 rearrangement occurs in a random manner and at a very low frequency, only one 
thymocyte in a million can potentially become an iNKT cell (32)..  Once iNKT cells develop 
in the thymus they will undergo a maturation process requiring the expression of 
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costimulatory molecules such as CD28, cytokine receptors, signal transduction molecules and 
transcription factors.  Following this process, some iNKT cells leave the thymus as NK1.1 
(CD161) negative cells and will acquire the expression of this molecule in the periphery, 
becoming mature iNKT cells.  A proportion of iNKT cells leave the thymus as NK1.1 
negative cells, but will never express NK1.1.This subpopulation has been proposed to have a 
different biological activity. Another subpopulation of NK1.1 negative NKT cells is thought 
to never leave the thymus. They acquire NK1.1 expression and are thought to become 
permanent residents of the thymus.  The mechanism underlying thymic export and retention 
of iNKT cells at the different stages of maturation is not well understood to date (reviewed in 
(30)).   
1.2.3.2 iNKT cell activation and function 
iNKT cells, once activated, play a role in many immunological processes including infection, 
transplant-rejection  and autoimmunity . 
Their activation occurs by the direct recognition of iNKT cells of an exogenous antigen or via 
the recognition of self antigens such as iGb3. The function of iNKT cells is not very well 
understood. It appears to vary depending on the situation as they have the ability to secrete 
different sets of cytokines in different scenarios.  
A cascade of events following iNKT cell activation by α-Gal-Cer has been proposed: α-Gal-
Cer is presented by resting DCs to iNKT cells through CD1d and iTCR interactions. This 
causes iNKT cells to secrete cytokines and chemokines as well as to upregulate CD40L 
surface expression. CD40L interacts with DCs through CD40. Interaction between iNKT cells 
and DCs is thought to cause DCs to secrete IL-12 which in turn enhances iNKT cell activation 
and cytokine production. Activated DCs then upregulate MHC class I and II molecules and 
present increasing amounts of antigen to CD4 and CD8 T cells. iNKT cells produce high 
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levels of IFN-γ and cause NK cell cytolysis. They also stimulate B cells to increase antibody 
production. It is not clear why iNKT cells produce Th1 or Th2 cytokines in different 
situations. Following massive cytokine production by iNKT cells, these cells have been 
suggested to undergo apoptosis. New iNKT cells are generated in the bone marrow but the 
process may take up to three to four days during which very few iNKT cells will be detectable 
in the circulation (reviewed in (17)). 
iNKT cell are known to produce IL-4, IFNγ, IL-2, IL-5, IL-6, IL-13, IL-17, IL-21, TNF-α, 
TGF-β and GM-CSF. In addition to these cytokines, iNKT cells also secrete a range of 
chemokines (33). Several transcription factors are known to regulate cytokine and chemokine 
production by iNKT cells such as NFkβ (34) or STAT6 (35). iNKT cells can also have 
cytotoxic activity. They express granzyme B, perforin and FasL. iNKT cells have been 
demonstrated to kill antigen-pulsed APC in vitro (36).  iNKT cells secrete cytokines that are 
activation signals for various cells including: CD4 and CD8 T cells, macrophages, NK cells 
and B cells. They also have an influence on the type of cells recruited; they can recruit 
neutrophils through IFN-γ production. IL-2 production by iNKT cells can modulate Treg 
function but in turn Tregs may act as a negative feedback mechanism for iNKT cell function 
by suppressing iNKT cell proliferation, cytokine production and reducing iNKT cells 
cytotoxic activities (reviewed by (37). 
In response to bacterial infections, iNKT cells can be activated via two different mechanisms, 
by direct presentation and recognition of bacterial antigen or triggering self activation by 
iGb3. Some bacteria, such as Sphingomonas contain a compound, known as 
glycosphingolipids (GSLs) in their cell wall (38). It has similarities to LPS. In Shingomonas 
infection, the bacterium is taken up by DCs and bacterial antigen is presented to iNKT cells 
via CD1d, these results in iNKT cell activation and cytokine production. On the other hand 
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many bacteria lack specific antigens that can be recognized by iNKT cells. These bacteria, for 
example, Salmonella have the ability to activate iNKT cells via an alternative pathway. LPS 
from gram negative bacteria is recognized by TLR4 on APC and this leads to iGb3 and IL-12 
production by APC. iGb3 is then presented to iNKT cells and they recognized it as a self 
antigen which triggers iNKT cell activation and subsequent cytokine production (reviewed in 
(17)). 
1.2.4 T cell activation markers.  
T cell stimulation leads to the upregulation of several cell surface molecules including CD25, 
CD69, CD71 and HLA-DR. Functionally, CD25, (39)  acts as the IL-2R alpha chain. Its 
expression is not specific to activated T cells but it is also expressed by Tregs and on activated 
B cells (40). CD69 is a very early activation marker, it belongs to the natural killer cell gene 
complex family and it is expressed on T cells within 30 minutes of TCR stimulation, it is 
involved in lymphocyte proliferation and it acts as a signal transducer for NK cells, 
lymphocytes and platelets (41-43). CD71, the receptor for transferrin, an iron-transport 
protein, mediates iron uptake, is normally expressed on resting lymphocytes at a very low 
level and is upregulated upon activation (44). Its expression is very closely associated with the 
S-phase of the cell cycle. HLA-DR is a human class II major histocompatibility complex 
antigen. HLA-DR can be detected in elevated levels at the later stages of T cell activation 
(45). 
 
1.3 Cytokines 
Cytokines are small proteins of about 25KDa. A large part of the information exchanged 
between cells of the immune system is transmitted through this group of soluble proteins. 
They affect the behavior of several cells in an autocrine and paracrine manner. There are two 
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structural families of cytokines: the hematopoietin family and the TNF family. The 
hematopoietin family includes several growth factors and interleukins, an example is IL-6. 
The TNF family of cytokines comprises 19 members including:  TNFα, receptor activator of 
nuclear factor κB ligand (RANKL) and Fas ligand (FasL) (reviewed in (46). Cytokines from 
both families play a role in both innate and adaptive immune responses. Cytokines can be 
both pro and anti-inflammatory, some favor the inflammatory process to fight an invading 
pathogen and some act in an anti-inflammatory fashion to  promote the termination of 
inflammation and help restore tissue homeostasis (2). 
1.3.1 The IL-6 family of cytokines. 
The IL-6 family of cytokines currently has ten members: IL-6, IL-11, LIF, OSM, ciliary 
neurotrophic factor (CNTF), cardiothrophin-1 (CT-1), cardiotrophin-like cytokine (CLC) and 
neuroprotein (NP). The various members of this family of cytokines are produced by a variety 
of cell types; T cells, monocytes, fibroblasts, osteoblasts, epithelial cells and some cancer 
cells. They are implicated in different processes such as inflammation, embryonic 
development, bone homeostasis and hematopoiesis (reviewed in (47)). 
1.3.2 IL-6. 
IL-6 is a single chain protein with a molecular mass of about 28kd. The gene encoding IL-6 
has been mapped to chromosome 7, it has been cloned and sequenced and it appears to 
contain four introns and five exons and shows a high degree of conservation. The IL-6 
encoding gene has three initiation of transcription sites and three TATA-like sequences 
(reviewed in (48)). 
IL-6 is a cytokine secreted by monocytes, lymphocytes, synoviocytes, fibroblasts and 
endothelial cells (49), it has mainly a pro-inflammatory effect with some anti-inflammatory 
functions. 
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 1.3.2.1 IL-6, functions 
IL-6 upregulates adhesion molecules and induces the production of other pro-inflammatory 
cytokines (50). IL-6 also upregulates genes that affect important cellular functions such as 
apoptosis, differentiation, proliferation and survival (51). It has been reported to induce 
differentiation of activated B cell into antibody-producing cells (reviewed in (52). IL-6 
promotes the differentiation of cytotoxic T cells, macrophages and megakaryocytes.  It 
induces secretion of several molecules by hepatocytes such as C-reactive protein (CRP) or 
hepcidin (reviewed in (48)). CRP is an acute phase protein that is produced during 
inflammation and it binds to microbes during infection to enhance phagocytosis (reviewed in 
(53)). Hepcidin, is a hepatic hormone that regulates the intestinal absorption of iron (Nemeth 
et al. 1271-76). Furthermore, IL-6 contributes to angiogenesis by promoting the production of 
vascular endothelial growth factor. It also is a growth factor for several cell types including 
mesangial kidney cells, B cells and some tumor cells (reviewed in (54)).  
1.3.2.2  IL-6 signalling. 
 
The IL-6 receptor complex mediates the biological activities of IL-6. It is a heterotetramer 
combining two IL-6R α chain (CD126) and CD130 proteins respectively. CD130 is a 
signaling molecule also used by receptors for other cytokines; IL-27, IL-11, LIF, OSM, 
CNTF CT-1, CLC and NP (reviewed in (51)). 
IL-6 classically binds CD126 directly; this causes homodimerization and phosphorylation of 
CD130 which in turn activates JAK 1 and 2. JAK phosphorylates tyrosine residues of STAT 3 
and STAT 1 molecules, these form homo and heterodimers and translocate to the nuclear 
compartment where they will bind to specific target sites on the DNA of genes such as bcl-2 
and bcl-xL. IL-6 binding to its receptor also stimulates the Ras-MAP Kinase cascade, and this 
activates transcription factors such as ELK-1 (51,55). 
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In addition to the direct signaling through the IL-6R/CD130 complex, IL-6 may signal 
through a process known as transsignaling. This occurs when the soluble form of IL-6 
Receptor (sIL-6R) forms a complex with IL-6. This sIL6R-IL6 complex binds to a dimer of 
CD130 (56) triggering the activation of ras/Map-kinase/ERK and Jak-STAT pathways as in 
direct signaling through CD126 (57). The sIL-6R can be formed by alternative splicing of 
mRNA or shedding of membrane bound CD126 (56). 
IL-6 has a limited capacity to signal directly through CD126 binding, as CD126 is expressed 
in only a few cell types such as leukocytes and hepatocytes. In contrast CD130 is expressed 
ubiquitously, this allows IL-6 to influence a wider array of cells via transsignaling (58).  
IL-6 Direct Signalling IL-6 Transignalling
CD130
IL-6
IL-6
IL-6R 
(CD126)
IL-6/sIL-6R 
complex CD130sIL-6R
 
Figure 4. IL-6 signalling. On the left hand side IL-6 direct signalling. On the right hand side IL-6 
signals via transsignaling. 
The importance of IL-6 transsignaling is highlighted in inflammation where stromal cells 
exhibit a CD126 low CD130 high phenotype and their responses to IL-6 are therefore via 
transsignaling. In recent studies it has been shown that leukocyte expression of IL-6R make it 
possible that the IL-6 signals to leukocytes both via classic signaling and transsignaling 
(reviewed in (59)). It has been shown that T cell apoptosis can be inhibited in the aqueous 
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humour of uveitis patients by IL-6 transsignaling (60), indicating that T cells can respond to 
IL-6 not only via direct signaling but also via transsignaling. 
In order to achieve IL-6 transsignaling sIL-6R must be available, there are several instances in 
which sIL-6R is released from various cell types. Human neutrophils shed IL-6R during 
apoptosis that can be induced by several causes such as cytokine deprivation or DNA damage 
(61). Naïve and memory CD4 T cells also produce sIL-6R following TCR activation, 
activated CD4 T cells shed sIL-6R in a mechanism mediated by ADAM-17 protease (62). In 
addition the levels of sIL-6R are elevated in serum of healthy individuals after severe 
exercise, the elevation is found on the second day of severe physical activity and the increase 
in sIL-6R correlated with an increase in CRP (63) 
1.3.2.3. Regulation of IL-6R expression 
 
IL-6R expression can be regulated by internalization or downregulation of mRNA levels 
coding for the IL-6R. IL-6 causes IL-6R downregulation by internalization, the IL-6-sIL-6R 
complex is internalized by endocytosis and subsequently most IL-6R is degraded in the 
lysosomal compartment. This mechanisms acts as negative feedback for IL-6 signal (55,64). 
In 1992, Falus et al studied the regulation of CD126 and CD130 on human cell lines of 
myeloid and lymphoid origin. They showed a downregulation of CD126 and CD130, at both 
protein and mRNA level, in U266 and BMNH cell lines treated with TPA. They also showed 
an inhibition of CD126 expression triggered by TPA in U937 cells but no effect on CD130. In 
their experiments they also demonstrated an upregulation of CD130 only in U266 cells. their 
data suggest that CD126 and CD130 regulation can be independent (65). In rat hepatocytes 
CD126 mRNA is upregulated by dexamethasone but this has no effect on CD130 mRNA. In 
addition IL-1 and IL-6 both separately and together cause the downregulation of CD126 
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mRNA (66). The downregulation of CD126 mRNA has been reported in human monocytes 
following LPS exposure  (67).  
1.3.2.4 IL-6 and signaling regulation 
There are two families of molecules that negatively regulate the response to IL-6; suppressor 
of cytokine signaling proteins (SOCS) and protein inhibitor of activated STAT (PIAS). There 
are 7 SOCS molecules named SOCS1 to 7.  Activation of IL-6 signalling through JAK and 
STAT3 initiates a pathway that limits the extent and duration of the IL-6 response by directly 
initiating SOCS1 and 3 de novo production (47). The expression of SOCS proteins is also 
upregulated by LIF, IL-11 and OMS (68,69). SOCS1 acts on JAK2 and TYK2, preventing 
phosphorylation of CD130, STATS and JAKs themselves (70). PIAS are another family of 
proteins that negatively regulate IL-6 signaling. PIAS are constrictively expressed on many 
cell types; PIAS1 and PIAS3 has been reported to bind to STAT1 and 3 respectively, 
preventing STAT1 and 3 mediated gene transcription (reviewed in (51)). The majority of 
proteins that interact with PIAS are subject to modification by small ubiquitin-related 
modifier (SUMO). PIAS work by promoting SUMOylation of their interaction partners, 
which results in an alteration in function, interaction or cellular localization. For example 
PIAS 4 stimulates SUMOylation of P53, increasing its transcriptional activity (reviewed in 
(71) 
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Figure 5. IL-6 signalling. Downstream events following IL-6 signaling and regulation. 
Adapted from (51) 
1.3.1.5. IL-6, chronic inflammation and a role for IL-6 in the transition from innate to 
acquired immunity. 
Inflammation is a generally beneficial process that occurs to eliminate a threat to the 
organism. To prevent damage to the organism, inflammation must be a tightly regulated 
process. It needs to be initiated rapidly to eliminate the immunological challenge and be 
downregulated leaving behind as little tissue damage as possible. Controlled termination of 
inflammation is critical. IL-6 has an important role promoting the acute phase response. In 
acute inflammation an increase of acute phase proteins, such as CRP, is observed. IL-6 
amongst other cytokines is responsible for the increased production of these proteins mainly 
by the liver (reviewed in (72)). In some cases acute inflammation fails to resolve, this is the 
case seen in chronic inflammatory conditions such as RA or Crohn’s disease (73). IL-6 
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influences cell recruitment, survival and clearance by apoptosis, all of these functions if dys-
regulated by high levels of IL-6 lead to failure to terminate acute immune responses which in 
turn become chronic and no longer beneficial for the host but rather detrimental (reviewed in 
(72)). In addition, IL-6 has been shown to rescue mouse resting T cells from apoptosis in 
vitro, suggesting that IL-6 may be a T cells survival signal in vivo (50) allowing T cell 
survival for long periods in situations such as chronic inflammation. Furthermore, IL-6 
promotes the development of proinflammatory Th17 cells and suppresses Treg development 
(74). Work in human and murine peritoneal infection has shown that IL-6/IL6R complexes 
can control the switch from primarily neutrophilic to mononuclear cell dominated infiltrates 
by regulating expression of chemokines expression. By controlling this pattern of leukocyte 
recruitment during peritoneal inflammation, sIL-6R released from the initial neutrophil 
infiltrate contributes to this temporal switch from acute to chronic inflammation. 
The role of inhibition of IL-6 in therapy of RA will be discussed in section 1.6.3. 
1.3.2 Interleukin 10 (IL-10) 
IL-10 was firstly identified by Mosman and colleagues in 1989 (75). It belongs to a family of 
cytokines that includes: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28 and IL-29 (76). All 
members of this family have two features in common, they bind to receptors with very similar 
structures and their genes have a similar exon/intron organization (77). Although these 
cytokines share some characteristics they have very different biological functions that are 
determined by the secreting cell, the cell receiving the signal and the environment in which 
the interaction happens (reviewed in (78)). 
The gene encoding human IL-10 has been mapped in chromosome 1q21-32 and contains five 
coding exons separated by four non-coding introns (reviewed in (79)). 
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IL-10 is produced by a wide variety of cells, the major sources of IL-10 include: Th2, Th1, a 
subpopulation of Treg known as Tr1, CD8+T cells, monocytes, macrophages, some subsets of 
DCs, B cells, granulocytes and some non-immune cells such as epithelial cells or tumor cells 
(80,81). Some of the regulatory effects of Tregs and Bregs are mediated by the secretion of 
IL-10 and IL-10 produced by DCs can induce Tr1 differentiation (82). 
1.3.2.1 The IL-10 Receptor 
IL-10 signals through a receptor complex composed of two chains of IL-10R1 and two chains 
of IL-10R2. IL-10R1 is expressed by all hematopoietic cells while IL-10R2 is expressed 
almost ubiquitously. IL-10 binds IL-10R1 with high affinity and IL-10R2 enables signal 
transduction. Following IL-10 binding to the receptor complex Jak1 is phosphorylated and 
activated and recruited to IL-10R1 while Tyk2 is activated and recruited to IL-10R2, these 
two proteins phosphorylate the receptor (83). STAT3 is phosphorylated and then forms 
homodimers. These are released from the receptor and travel to the nuclear compartment 
where they will bind specific DNA motifs (84). STAT1 and 3 bind to the IL-10 gene 
promoter sequence and thus can positively regulate IL-10 expression in a positive feedback 
loop. STAT3 also activates expression of SOCS3 which in turn has a negative regulatory 
effect on IL-6 but not on IL-10 mediated signals. (reviewed in (79)). 
  
1.3.2.2 IL-10, Biological activity 
One of the main biological functions of IL-10 is to reduce the functional activity of APC(85). 
IL-10 reduces expression of MHC class II and co-stimulatory molecules CD80 and CD86 on 
DC and macrophages, preventing these cells from presenting antigen to T cells. It also has 
been suggested to prevent the activation of Th1 and Th2 cells and their secretion of cytokines. 
IL-10 also prevents maturation of monocytes to DCs. It not only prevents inflammation by 
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inhibiting pro-inflammatory events but also has a direct anti-inflammatory function by 
inducing production of IL-1 receptor antagonist.  
Even though, traditionally, IL-10 is seen as a potent anti-inflammatory cytokine it also has 
very important pro-inflammatory functions. It induces recruitment of CD8 T cells and 
stimulates its proliferation and cytotoxic activities. It also stimulates the proliferation of B 
cells, enhancing their antibody production (86). Furthermore, it stimulates NK cells to 
proliferate and produce cytokines. Interestingly, all proinflammatory effects of IL-10 appear 
to be dose dependent and this may explain why IL-10 caused adverse effect in patients treated 
with rIL-10 (reviewed in (87). 
Even though IL-10 has several proinflammatory functions it is largely known for its anti-
inflammatory properties. On the other hand, IL-6 is a well established pro-inflammatory 
cytokine. Paradoxically, both IL-6 and IL-10 signals activate STAT3. It is not very well 
understood why cytokines using the same signaling pathway can trigger such opposite effects. 
Yasukawa and collaborators proposed that SOCS3 prevents STAT3 activation by IL-6 but not 
IL-10, SOCS3 could therefore be a factor in the different effects triggered by IL-6 and IL-10 
(56). 
As I have previously mentioned cytokines regulate important physiological processes and 
excess cytokine activity can be harmful, therefore cytokine signaling must be modulated. 
There are several ways to in which the immune system modulates cytokine signaling, for 
example downregulating cytokine receptor expression by endocytosis or allowing a soluble 
form of the receptor to bind to the cytokine blocking cytokine binding to its cellular bound 
receptor.  
IL-6 and IL-10 are cytokines with very different biological functions but they both activate 
the JAK-STAT pathway. Both IL-6 and IL-10 lead to the activation of STAT3. Activated 
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JAKs phosphorylate parts of the cytokine receptor and create binding sites for SH2 domain 
containing proteins. JAK activation leads to STAT activation. IL-6 activates JAK1 and 
STAT3, while IL-10 activates tyk2 and STAT3. SOCS proteins interfere with the activation 
of the JAK-STAT pathway. For example the SH-2 domain of SOCS1 binds to JAK1 while the 
SH2 domain of SOCS3 binds to Y757 in mice and 759 in humans of the intracellular domain 
of gp130.  Once SOCS3 binds gp130 in proximity to JAK sites it inhibits JAK activity 
through kinase inhibitory region, which it is thought to act as a pseudosubstrate. There is also 
literature suggesting that blockade of binding of SHP2 to Y757 leads to subsequente blockade 
of MAPK and Pi3K activation (reviewed in (88). 
One may wonder why the activation of the same transcription factor STAT3 by IL-6 and IL-
10 leads to complete different effects. A clear difference between these two cytokines is the 
fact that SOSC3 prevents the activation of STAT3 by IL-6 but not by IL-10. It has been 
shown that STAT3 activation by IL-6 is suppressed in wild type mice macrophages in the 
presence of LPS whereas IL-10 STAT3 activation is not affected, in addition, IL-6 STAT3 
activation is not suppressed in macrophages from SOCS3 deficient  mice, indicating that 
SOCS3 is an essential regulator of STAT3 induced by IL-6 but not by IL-10 (89). SOCS3 is 
thought to have an important role in reducing inflammation in macrophages. In addition it has 
also been shown that STAT3 phosphorylation is prolonged in SOCS3 deficient mice 
macrophages following stimulation with IL-6 but not IL-10 (90). 
IL-6 and IL-10 have different effects when activating STATS3 and possibly an important 
factor in these differences is SOCS3, as it clearly suppresses the downstream effect from 
STAT3 when activated by IL-6 and not IL-10 (reviewed in (88).  
1.4 Inflammation  
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An inflammatory response is a physiological mechanism to defend the body against physical 
injury or an invading pathogen.  
1.4.1 Acute Inflammation 
The hallmarks of acute inflammation are calor (heat), dolor (pain), rubor (redness), tumor 
(swelling) and function laesa (loss of function). 
Acute inflammation is characterized by an influx of mainly Polymorphonuclear Neutrophils 
(PMN) to the site of injury in order to eliminate the inflammatory stimuli. Neutrophil 
presence at the site of immunological challenge peaks within 6 hours. Neutrophils are 
generated in the bone marrow; they migrate from the bone marrow into the bloodstream 
where they circulate until they are needed at the site of inflammation. When the immune 
system is challenged by an invading pathogen, acute inflammation involves release of 
mediators of acute inflammation, such as histamine produced by tissue resident mast cells. 
Furthermore, cytokines and chemokines are released by locally activated fibroblasts. This 
causes endothelial cells to bind and present chemokines and to express E-selectins and P-
selectins, these molecules bind to mucins expressed at higher levels on neutrophils as a 
consequence of acute inflammatory mediators such as IL-1 or TNF-α. The interaction 
between selectins and mucins results in attachment of neutrophils to vascular endothelium, 
neutrophils then roll in the direction of the blood flow. Other inflammatory molecules then act 
upon neutrophils causing them to undergo conformational changes that will result in 
neutrophil transmigration through the vascular endothelium. At this point, neutrophils will 
accumulate at the site of injury due to the presence of several chemoattractants. Neutrophils 
express Fc receptors and complement receptors which allow them to bind to complement or 
antibody coated pathogens facilitating their phagocytosis. Neutrophils also release reactive 
oxygen and nitrogen intermediates which contribute to pathogen killing and also to the tissue 
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damage resulting from inflammation. Neutrophils secrete pro-inflammatory molecules such as 
MIP-1α and MIP-1β which are chemoattractants for macrophages. Activated macrophages 
contribute to phagocytosis of pathogens and release 3 key cytokines: IL-6, IL-1 and TNF-α. 
These 3 cytokines contribute to the inflammatory process by local and systemic changes, they 
induce the expression of ICAM-1 and VCAM-1 on the endothelium, circulating monocytes, 
neutrophils and lymphocytes bind to these molecules via integrin interactions. IL-1 and TNF 
trigger cytokine realize from macrophages contributing to neutrophil recruitment. IFNγ and 
TNFα activate macrophages and prime neutrophils (1). 
Local inflammation may be supported by systemic changes known as an acute phase 
response; these changes are caused by the effect of IL-1, TNF-α and IL-6. The acute phase 
response involves elevated body temperature; include the production of several hormones 
such as ACTH or hydrocortisone leading to an increase of white cell production by the bone 
marrow and production of acute phase proteins by the liver. Among these is CRP, a hallmark 
of inflammation produced by  hepatocytes upon IL-6 stimulation (91). 
1.4.2 Chronic Inflammation 
The hallmark of chronic inflammation is the accumulation of activated macrophages and 
lymphocytes at the site of infection or injury. Activated macrophages secrete TNFα, while 
IFNγ is produced by Th1, NK cells and cytotoxic T cells. IFNα acts on macrophages and 
increases their production of TNFα. Both cytokines cause the upregulation of ICAM1 and E-
selectin expression, thus facilitating the recruitment of more immune cells to the site of 
inflammation. The recruited cells will produce cytokines and inflammatory mediators and 
contribute to the process. In chronic inflammation, fibrosis can occur as a result of excessive 
collagen production by fibroblasts. In some chronic inflammatory diseases, such as in 
sarcoidosis, granulomas can form. These are organized structures mainly consisting of 
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activated and differentiated macrophages often surrounded by T -cells. Characteristically, 
fusion of macrophages to multinucleated giant cells can be observed in these structures. 
The persistent release of release reactive oxygen and nitrogen intermediates contributes to the 
extensive tissue damage seen in chronic inflammation (2). 
Chronic inflammation is seen in several autoimmune diseases such as RA and in situations a 
pathogen cannot be cleared by the immune system. An example for a chronic infection that is 
often not cleared, but kept under control by formation granulomas is tuberculosis (1).    
1.4.3 Resolution of Inflammation 
The resolution of inflammation is a process in which all infiltrating inflammatory cells are 
removed from the site of inflammation and tissue homeostasis is restored. The resolution 
phase was in the past thought to be a passive process in which the chemical mediators of 
inflammation would gradually disappear once the inflammatory challenge was eliminated 
(reviewed in (92)). Today, the resolution of inflammation is understood as a complex active 
process in which several biochemical pathways are specifically regulated (reviewed in (93)). 
An imbalance in the mechanisms involved in the resolution phase of inflammation results in 
failure to resolve inflammation which in turn may lead to chronic inflammatory conditions 
such as Rheumatoid arthritis (RA)(92). During acute inflammation, PMN synthesize 
proinflammatory lipid mediators such as eicosanoids.  However, recent work has shown that 
during inflammation neutrophils can change their phenotype and start producing anti-
inflammatory mediators to actively switch off acute inflammation and promote resolution. To 
date there are three types of molecules known to actively resolve inflammation: lipoxins, 
resolvins and protectins (93). Lipoxins are derivates of arachidonic acid (94). 
Proinflammatory cytokines IL-1β and IL-4 promote the expression of lipoxins. The main 
action of lipoxins is to decrease PMN recruitment to the site of inflammation. Resolvins and 
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protectins are recently identified anti-inflammatory molecules. They are very potent anti-
inflammatory mediators; their mode of action includes decrease of production of pro-
inflammatory molecules and down-regulation of recruitment of inflammatory cells to the site 
of inflammation. Protectins, on the other hand, stop PMN cell infiltration by downregulation 
of cytokine expression for example  by glial cells (reviewed in (92)). 
 
1.5 Rheumatoid arthritis (RA) and classification criteria 
RA is a chronic systemic inflammatory disease affecting the joints. The etiology and 
pathogenesis of RA are still not fully understood. It affects approximately 1% of the 
population worldwide (95) being five times more frequent in the indigenous population of 
North America compared to Caucasians (96). It is also more commonly found in females than 
in males with a female to male ration of 2-3:1. It may affect individuals of all ages but there is 
a peak onset between 40 and 60 years of age (reviewed in (97)) 
Genetic and environmental factors have been suggested to play an important role in the origin 
of RA (98). About 60% of susceptibility is accounted for by genetic factors (reviewed by 
(99)). An association has been described between RA and a sequence motif present in the 
hypervariable region of the β-chain of the HLA-DRB1 molecule (100). Several infectious 
agents such as Borrelia burgdorferi or rubella virus can induce a clinical syndrome difficult to 
distinguish from RA, most likely by molecular mimicry mechanisms (reviewed by (101,102)) 
.So far no infectious agent has been conclusively associated with RA development (103,104). 
Since, at least during their reproductive years, RA is more frequent in females, sex hormones 
have been proposed as another susceptibility factor for RA (105). Many other environmental 
factors have been linked with an increased risk of developing RA such as smoking (106,107). 
Overall the current perception is that RA is a multifactorial disease and that in a genetically 
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susceptible individual environmental factors will trigger joint inflammation and RA 
development (reviewed in (101). 
Typical symptoms seen in RA such as joint pain and swelling are not very specific to this 
disease, in fact patients affected with other rheumatic diseases such as SLE or psoriatic 
arthritis may present to the clinic with similar complaints. To be able to diagnose RA and 
distinguish it from other conditions, several classification criteria have been developed. The 
first set of criteria to be used to differentially diagnose RA was the ARA criteria created in 
1956. New developments led to their revision in 1987. Currently another revision is on its 
way; the new set of criteria is expected to be announced shortly in 2010. In the long term it is 
expected research into new genetic and immunological tools will further improve diagnostic 
criteria and will also allow the segregation of subsets of patients with different prognoses and 
optimized treatment choices. The ARA revised criteria is shown in table 1 (reviewed in 
(108)). 
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Criterion Definition 
1. Morning Stiffness Morning stiffness in and around the joint 
lasting at least one hour before maximal 
improvement. 
2. Arthritis in three or more joint areas At least three joint areas simultaneously 
having soft tissue swelling or fluid (not 
bony overgrowth alone) observed by a 
physician (the 14 possible joint areas are 
[right or left] PIP, MCP, wrist, elbow, 
knee, ankle, and MTP joints). 
3.Arthritis of hand joints At least one joint area swollen as above 
in wrist MCP or PIP joint. 
4. Symmetric arthritis Simultaneous involvement of the same 
joint areas (as in criterion 2) on both sides 
of the body (bilateral involvement of PIP, 
MCP or MTP joints is acceptable without 
absolute symmetry). 
5.Rheumatoid nodules Subcutaneous nodules over bony 
prominences or extensor surfaces, or in 
juxta-articular regions, observed by a 
physician. 
6. Serum rheumatoid factor Demonstration of abnormal amounts of 
serum “rheumatoid factor” by any 
method that has been positive in less than 
5% of normal control subjects. 
7. Radiographic changes Changes typical to RA on PA hand and 
wrist radiographs, which must include 
erosions or unequivocal bony 
decalcification localized to or most 
marked adjacent to the involved joints 
(osteoarthritis changes alone do not 
qualify) 
 
 
1.5.1 Immunobiology and origin of Rheumatoid arthritis. 
Neither the origin nor pathophysiology of RA are fully understood but many efforts have been 
made to investigate both. Many cells and molecules such as B cells, T cells, synovial 
fibroblasts, IL-6, TNF-α among others are present in the inflamed joint, but the overall role of 
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each of these players and the causative agent of the disease have not yet been reliably 
identified. Considerable effort has been made to understand T cell involvement in RA. There 
is no conclusive evidence for T cell clonal expansion to a particular antigen in the rheumatoid 
joint. However, a HLA-restricted T cell response has been postulated since 80% of RA 
patients among the Caucasian population have a shared epitope across the HLA-DR1 and 
HLA-DR4 haplotypes (109).The shared epitope is a 5-aa sequence motif in the third allelic 
hypervariable region of the HLA-DRβ chain (110), The presence of hypermutated IgG 
antibodies in 50% of RA patients suggests there could be an important autoantigen in RA 
triggering T cell activation (reviewed in (111)). T cells can be important mediators of disease 
pathology by antigen driven activation or triggering antigen-independent responses. RA T 
cells trigger TNF-α production by monocytes via contact dependent interactions  (112). It has 
been shown as well that T cells may play a role that does not rely on antigen activation. T 
cells can be activated by a cytokine cocktail (IL-6, IL-2 and TNF-α), independently of antigen 
(113). Cytokine activated T cells can induce contact independent production of IL-6 by 
synovial fibroblasts (114). Brennan et al showed that RA synovial T cells are in fact similar to 
cytokine activated T cells (115). Independently of the mode of activation, it is clear that T 
cells are an important player in the RA pathology as treatment with Abatacept, a recombinant 
construct of CTLA-4 and IgFc that blocks T cell activation by interfering with signaling 
through costimulatory molecules (CD28 and B7) is proven clinically effective trials (116). 
The role of T cells in RA will be discussed in section 1.5.4. 
B cells are also important in RA. They produce antibodies and inflammatory mediators such 
as cytokines and chemokines. In addition, B cells can act as APC in RA triggering T cell 
activation which in turn results in macrophage activation and further TNF-α production (117). 
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Treatment with rituximab, an anti-CD20 antibody, which works by depleting B cells, has been 
successfully used in clinical trials, highlighting the important role of B cells in RA (118). 
Various autoantibodies have been described to date in RA, such as RF and antibodies to 
immunoglobulin binding protein (reviewed in (119)). More recently antibodies to citrullinated 
proteins (ACPA) have been described. They are very specific markers of the disease but their 
particular role in the pathogenesis has not yet been elucidated. Antibodies to citrullinated 
peptides were shown in the CIA model following Type II collagen immunization and prior to 
disease symptoms and it was further demonstrated that antibodies to citrullinated peptides 
enhances tissue damage in the mice (119). 
Even though the research of the past years have shown advances in the understanding of RA, 
the overall disease process, the interactions between inflammatory cells and inflammatory 
mediators and a the overall cause of RA are not well understood to date. 
1.5.2 The synovium, in health and in RA. 
Under normal circumstances the synovial membrane that covers the inner surface of the joints 
is a thin layer of tissue of about 5mm thickness. The individual cells that compose the 
synovial membrane are known as synoviocytes. Two types of synoviocytes have been 
identified; macrophage-like or type A and fibroblast-like or type B synoviocytes (120). Type 
A synoviocytes or synovial macrophages are derived from bone marrow derived monocytes. 
They express several surface markers typically seen in macrophages including MHC class II 
molecules, CD68 and CD14 (121-123). In contrast, type B synoviocytes, or synovial 
fibroblast, most likely originate from mesenchymal progenitors in the synovium, and they 
express the adhesion molecules VCAM-1 (121,124) and α6β1 integrin (125). Synoviocytes 
can secrete large amounts of hyaluronic acid. However under inflammatory conditions they 
secrete matrix-degrading enzymes.  The synovium is an organized structure of lining and 
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sublining that resembles the structures of epithelium and endothelium. The synovial cavity is 
filled with synovial fluid (SF), a viscous fluid that contains hyaluronic acid and lubricin and 
prevents cartilage friction and lubricates the joint. (reviewed in (126)). 
Under inflammatory conditions such as RA the synovium becomes thicker and invasive; it 
invades the cartilage and bone contributing to the devastating effects of RA. Three key events 
occur in the synovium in RA: synovial hyperplasia, angiogenesis and infiltration of the 
synovium by immune cells. Synovial hyperplasia is characteristic of RA, the lining layer of 
the synovium becomes thicker with a depth of about 8 cells when it was compared to a layer 
of one  cell depth in healthy controls (127). Synoviocytes  become activated in patients with 
RA and exhibit higher activity of various transcription factor including NF-kβ, which is 
involved in the expression of adhesion molecules, inflammatory cytokines as well as matrix-
degrading enzymes, all important mediators of RA pathophysiology (125). As described 
above, in RA the synovium becomes thicker with a larger number of cells that require 
nutrition and oxygenation to be brought by the bloodstream. As the requirement for nutrition 
grows angiogenesis is triggered in the synovium. Without the formation of new blood vessels 
the increased number of cells could not survive. Angiogenesis is encouraged by the 
production of several factors such as VEGF or PDGR (128,129). Experiments in animal 
models have shown the importance of angiogenesis in the pathophysiology of RA-like 
disease. Inhibition of angiogenesis prevented the development of CIA in mice (130). Finally, 
a central event in the development of RA is the infiltration of immune cells. Various cells 
types are found in the rheumatoid synovium: neutrophils, T cells, B cells, NK cells, DC and 
mast cells (reviewed by (126). The role of all these cell types has been extensively studied but 
the actual pathological mechanism and how all these cells and their secreted products interact 
with each other has yet not been fully clarified. 
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Figure 6. Healthy versus RA joint. The Join in health and in RA. Left hand side shows the 
schematic representation of a healthy joint. On the right the representation of a RA joint. 
1.5.3  RA, a two phase disease  
 Many people in the course of their lives may present with joint inflammation, many of these 
patients will resolve the inflammation, some others will develop inflammatory conditions 
other than RA, such as psoriatic arthritis and some will go on to develop RA. One of the main 
areas studied in this project is the pathophysiology of very early arthritis patients (VEA), with 
this term we refer to patients presenting with joint inflammation for a period no longer than 3 
months. It is important to identify as soon as possible those VEA patients which will go on to 
develop RA as treatment is more efficient when administrated at an early stage of the disease 
(reviewed in (131)).  
In a previous study, we have identified a number of that cytokines are only present in the SF 
at a very early stage, up to three months from symptom onset. These include: IL-2, IL-4, IL-
13, IL-17, IL-15, basic fibroblast growth factor and epidermal growth factor. This transient 
and distinct early cytokine profile found in early RA patients  suggests that there may be two 
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phases in the pathology of RA (132).  The source of these cytokines is currently being 
investigated in a separate project in our group. 
1.5.4 T cells in RA 
As discussed in 1.5.1 T cells have been proposed to have a central role in the pathology of 
RA. Although there are other inflammatory cells present in the RA synovium, T cells are 
found in greater numbers than any other lymphocyte (133). The majority of T cells in the 
synovium are found forming clusters around perivascular areas and smaller numbers T cells 
can be found scattered in the RA synovium (134). 
 During inflammation in response to pathogen invasion or tissue damage large numbers of T 
cells are recruited to the site of injury (135). Under normal circumstances, when the challenge 
is removed and the inflammatory response in no longer necessary, the majority of T cells 
undergo apoptosis (136) caused by cytokine deprivation (137). In RA highly differentiated T 
cells fail to undergo apoptosis and are kept alive in the synovium by several stromal factors 
such as IFN-β. The ability of the synovial microenvironment to rescue T cells from apoptosis 
contributes to T cell accumulation and RA chronicity (138,139). 
1.5.4.1 T cell distribution and phenotype in the rheumatoid synovium. 
T cells in the synovium of a RA patient display particular phenotypic characteristics, they 
express activation markers such as CD69 and HLA-DR, but they are hyporesponsive to 
antigen stimulation (140,141).They express a wide array of  other surface molecules including 
chemokine receptors such as CCR5, CCR6 (reviewed in (142). They also express 
costimulatory molecules including ICOSL, OX40 and CD28, and receptors for many 
cytokines such as IL-1R, IL-25R, IL-23, etc which enable them to be targeted by several 
cytokines (reviewed in (143)). 
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Several different types of inflammatory infiltrates can be distinguished in the rheumatoid 
synovium: The synovial infiltrate can be a diffuse infiltrate of T cells, B cells and 
macrophages and DCs; In a subgroup of patients these can form follicular clusters of B, T and 
dendritic cells; organized structures resembling germinal centers or in rare occasions lesions 
resembling granulomatomata have been described (144-146). Germinal centre like infiltrates 
are of particular importance as they may indicate hypermutation and selection of high affinity 
B cell clones in the synovial tissue (146). The type of infiltrate seems to be stable and is often 
observed in different joints of the same patient (147).   
1.5.4.2 Potential T cell antigens in the synovium 
Autoimmunity involves the recognition of self-antigens by autoreactive T and B cells and the 
initiation of an anti-self immune response. In the context of RA researchers have been 
searching for joint specific self antigens that could trigger the disease. Possible candidates 
identified so far include type II collagen, HCgp-39 (a cartilage protein) and proteoglycans 
such as aggrecan. These antigens are able to cause murine autoimmune arthritis (148-150). 
More recently, however greater interest has been given by scientists to citrullinated proteins 
as potential RA autoantigens (reviewed by (143). 
1.5.4.3 Interactions of T cells with other cells in the rheumatoid joint. 
T cells can interact both with infiltrating immune cells as well as with stromal cells resident in 
the joint. These interactions can occur through direct cell to cell contact or via secreted factors 
such as cytokines. T cells and NKT cells are activated by interactions with DCs (151). While 
the existence of antigen specific T cells in the rheumatoid synovium is still a matter of 
considerable debate, the efficacy of treatment with soluble CTLA-4 Fc constructs that block 
costimulation suggests that T cell activation is an important process even in established 
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disease. T cells in the rheumatoid synovium have been compared to T cells activated in vitro 
by a combination of cytokines (113). 
Interaction between T cells and monocytes through CD40-CD40L interaction can lead to 
osteoclastogenesis. This process is dependent on RANKL and enhanced by several cytokines 
including IL-15, IL-17, TNF and IL-1 (152). The process of osteoclastogenesis is enhanced 
by further interaction of T cells with synoviocytes, requiring the presence of TNF and IL-1 
(153). 
T cells found in RA synovium can acquire expression of chemokine receptor CX3CL1 or the 
NK receptors KIR2DS2 and NKG2D (reviewed in (142) . Fractalkine-producing synoviocytes 
can therefore stimulate T cell activation and proliferation through the interaction with its 
newly expressed receptor (154). Expression of the NK cell related receptors confers the 
ability to respond to activated protein C to synovial T cells.  The generation of hypermutated  
IgG antibodies is a process that depends upon cell cell contact and cognate interaction 
between T cells and B cells. Since both anti-citrullinated protein antibodies and a proportion 
of rheumatoid factor are IgG, such an interaction is likely to take place in patients with 
rheumatoid arthritis. Whether this interaction takes place in the synovium or in draining or 
distant lymph nodes remains subject of discussion   (reviewed in (143)).  
1.5.4.4 Role of the newly identified Th17 T cell subset in RA 
Traditionally RA has been considered as a Th-1 like disease in which characterization of T 
cells from synovial origin from established patients revealed expression of Th-1 cytokines 
such as IFN-γ and TNF-α (reviewed in (155)). It has been proposed that a defect in Th2 
differentiation mechanism leads to the lack of Th2-like cytokines and allows Th1 cytokines to 
dominate the situation leading to chronic inflammation. It has been proposed that the 
mechanisms underlying Th2 differentiation defects are IL-4R allelic variations and 
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consequently attenuated STAT-6 activation and GATA-binding protein 3 induction, both  
requisites for Th2 differentiation (156). 
Recently a newly identified Th subset, Th17 cells, has been proposed to have a critical role in 
RA. This T cell subtype is characterized by the production of IL-17 and IL-22.  IL-17 is a 
strong effector inflammatory cytokine; its effects include the induction of cytokine secretion 
such as TNF, IL-1 and IL-6. IL-17 stimulates stromal cells, neutrophils, macrophages, 
osteoclasts and chondrocytes contributing to bone and cartilage degradation seen in RA 
(reviewed in (143)). 
The role of IL-17 in arthritis has been studied in the context of CIA. In CIA IL-17 produced 
by CD4 positive T cells unable to produce IFN-γ was pathogenic. IL-23 is a requirement for 
the survival of Th17 cells. IL-23 deficient mice failed to develop CIA (reviewed in (157)).  
In the synovial fluid and tissue of patients with RA high levels of IL-17 are 
detectable(158,159) other cytokines present in the rheumatic joint; particularly IL-1β, IL-23 
and IL-6 are known to support Th differentiation towards Th17.  
1.5.4.5 Regulatory T cells in RA 
The role of Treg in RA has received considerable attention recently. Their role has been 
highlighted in several animal models. When DBA/1 mice are depleted of Tregs using anti-
CD25 antibodies CIA becomes more several than under normal conditions (160). Mice with a 
gene mutation in the Foxp3 coding gene, essential for Treg function, develop a multi organ 
autoimmunity, these mice are known as scurfy mice (reviewed by (9). In patients with 
Idiopathic juvenile arthritis,  numbers of CD4+CD25bright T cells are reduced, supporting the 
idea that Tregs may be beneficial against autoimmunity (161). In RA PB and SF the number 
of Tregs seem to be comparable to healthy PB and SF from other conditions (162,163). 
However, Treg functionality has been demonstrated to be decreased or impaired in RA SF and 
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PB. Under normal circumstances Tregs suppress TNF-α and IFN-γ production by CD4 T 
cells, in SF Tregs fail to do so this, which in turn results in maintained effector T cell 
proliferation (163). Ehrenstein and coworkers showed that Tregs from RA patients were 
unable to prevent proinflammatory cytokine production by T cells and monocytes, in addition 
they showed that TNF-α treatment (infliximab) restored the ability of Tregs to suppress T cell 
and monocyte cytokine production as well as to cause a rise in the number of circulating 
Tregs which coincided with amelioration of disease symptoms (164). In addition, TNF-
α overexpression in the synovium increases the expression of TNF type II receptor which has 
the effect of lowering Foxp3 expression. Foxp3 is essential for the suppressive effects of 
Tregs in other cells, the decreased levels of Foxp3 translate in decreased ability to suppresses 
other immune cells (165). This may suggest that Treg involvement in RA may not be due to 
abnormal development but is more likely explained by the altered functionality of these cells.  
1.5.5 iNKT cells and autoimmune disease 
Due to the ability of NKT cells to secrete large quantities of immunomodulatory Th1 and Th2 
cytokines, these cells have been implicated in immune responses controlling several diseases 
such as infection, cancer or autoimmunity (18). 
iNKT cells may help to maintain tolerance to self-antigens and therefore contribute to the 
prevention of  autoimmunity (reviewed in  (21)). 
The levels of iNKT cells in the peripheral blood have been found to be reduced in patients 
suffering from several autoimmune diseases and in transgenic mice prone to autoimmune 
disease. In addition, estrogens have been found to induce IFN-γ secretion by iNKT cells, this 
could contribute to the differential sex distribution of autoimmune diseases (166). 
Multiple Sclerosis (MS) is an autoimmune disease in which an immune response is mounted 
against the myelin sheath covering the nerves. In this autoimmune disease IL-4 secretion by 
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iNKT cells was reduced and a reduction was also found in the mRNA levels for Vα24 in the 
peripheral blood of MS patients. 
iNKT cells have also been associated with the pathogenesis of Type I diabetes. In the murine 
Type I diabetes model, non-obese diabetic mice (NOD mice), the numbers of iNKT cells have 
been reported to be low and their function defective, and disease progression is ameliorated 
by the adoptive transfer of iNKT cells. 
Similarly in the Swiss Jim Lambert (SJL) murine model for autoimmune encephalomyelitis 
there are reduced numbers of iNKT cell and reduced IL-4 production by iNKT cells. 
In patients suffering from Lupus Erythematosus as well as in lupus susceptible mice, iNKT 
cell levels were reported to be reduced. However the transfer of activated iNKT cells to 
susceptible young mice induced an autoimmune inflammatory reaction (reviewed in (167)). 
Recent studies suggested a link between iNKT cells and animal models of the autoimmune 
disease bronchial asthma. In BALB/c mice, airway hyperesponsivenes (AHR) can be induced 
by challenging the mice with Ovalbumine (OVA). CD1d deficient mice and iNKT cells 
deficient mice failed to develop AHR after OVA sensitization. But when iNKT cells were 
transferred to iNKT cell deficient, OVA challenged mice, the AHR was restored. In addition, 
iNKT cells present in the airways of asthma patients have been reported to produce Th2 type 
cytokines, which seems to contribute to the Th2 phenotype seen in this autoimmune disease 
(29).    
Due to their ability to modulate the immune response iNKT cells have to be carefully 
regulated to not contribute to the development of autoimmunity. 
1.5.6 NKT cells and RA 
iNKT cells have been associated with RA in many studies. However the specific role of this 
cell type in the pathology of RA is not fully understood yet. A protective role for iNKT cells 
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against the development of RA has been reported by Chiba and colleagues (168). In contrast, 
other groups suggest that the presence of these cells may be detrimental in RA pathology. The 
CIA murine model has been used by several groups to elucidate the role of iNKT cells in RA. 
Administration of OCH, an α-GalCer analogue, was shown to be of therapeutic value in the 
CIA mouse model, while it did not alter the outcome of the disease in iNKT deficient mice 
(168). When IL-4 and IL-10 blocking antibodies were administrated in CIA OCH treated 
mice the effects of OCH treatment were suppressed. It was therefore suggested that OCH may 
induce a shift from Th1 to a protective Th2 immune response mediated by iNKT cells. The 
usage of α-GalCer as a therapeutic agent is controversial as conflicting results have been 
reported. Chiba A. and colleagues reported no benefits from α -GalCer administration in the 
CIA mouse but Miellet et al 2005 reported attenuated clinical signs of arthritis following 
prophylactic and therapeutic administration of α-GalCer in the CIA mouse. Involvement of 
iNKT cells in CIA was confirmed in iNKT cell deficient mice. Upon type-II collagen 
immunization the iNKT cell deficient mice developed a much less severe arthritis and 
inhibition of CD1d by monoclonal antibodies, blocking therefore the interaction between 
CD1d and iNKT cells in the CIA mice also resulted in a suppression of arthritis. 
In a further murine model, Antibody Induced Arthritis (ABIA), iNKT cells have not been 
linked with a protective effect against the disease but rather suggested a harmful role. ABIA is 
induced in a healthy mouse by transferring Immunoglobulins from the K/BxN mice which 
spontaneously develops an autoimmune inflammatory condition affecting the joints (reviewed 
in (169)). iNKT cell deficient mice failed to develop ABIA, and the activation of iNKT cells 
by administration of α -GalCer resulted in aggravation of the disease. It was also reported that 
in CD1d deficient mice the levels of Transforming Growth Factor-β (TGF- β) were elevated 
in the joint (170). The same group reported later on that iNKT cells express FcγRIII and that 
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FcγRIII engagement by IgG causes iNKT cells to become activated and produce IL-4, IL-10, 
IL-13 and IFN-γ within the context of ABIA (171). It is possible that iNKT cells activated by 
IgG through FcγRIII engagement produce pro-inflammatory cytokines that downregulate the 
production of TGF-β in the joint which in turn contributes to the inflammatory process seen in 
ABIA (reviewed in (27)). 
1.5.7 IL-6 and RA 
The first evidence that IL-6 plays a role in RA pathology derives from the observation that IL-
6 is present at high concentrations in the SF of RA patients (172). Some of the systemic 
symptoms observed in an RA patient, such as fever or autoantibody production, can be 
associated with excess production of IL-6, and the blockage of IL-6 has proven to ameliorate 
the clinical signs of RA (173,174). An increase in RA susceptibility has been associated with 
polymorphisms detected in the IL-6 promoter, in particular the -174G>C (175). IL-6 promotes 
the development of Th17 cells, clear  contributors to autoimmunity, via IL-gp130-STAT3 
pathway while it suppresses the development of Tregs (74). 
IL-6 has also been demonstrated to play a role in the development of autoimmunity and in 
particular the development of RA in several animal models. Using a model of Antigen 
Induced Arthritis (AIA) Boe and colleagues illustrated the role of IL-6 disease pathology 
(176). For this purpose, they induced AIA by injecting the mice with methylated bovine 
serum albumin, in both wild-type and IL-6 deficient animals. They observed that while wild 
type mice developed arthritis, IL-6 knockout mice fail to present any of the symptoms 
typically seen in this model. Furthermore, when IL-6 was injected into IL-6-/- mice, they were 
able to induce AIA (176).  Alonzi and coworkers injected IL-6-/- DBA/1J mice with type II 
collagen and complete Freund's adjuvant, in wild type mice. Under these circumstances, type 
II collagen injection leads to Collagen Induced arthritis (CIA). CIA is a murine animal model 
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of arthritis often used to study the pathogenesis of arthritis and to investigate possible 
treatment strategies. Susceptible mouse strains, if immunized with type-II collagen, raise a 
severe B and T cells response, characterized mainly by the presence of Th1-type cytokines. 
Mice deficient in IL-6 failed to develop this condition (177). These animal models suggest 
that the contribution of IL-6 is essential for the development of arthritis in mice. However, 
some controversial results were shown using the K/BxNOD (KBN) murine model where IL-6 
was not necessary for the induction of arthritis (178).  
Synovial fibroblasts have an active role promoting inflammation in the synovium. They 
produce a variety of inflammatory mediators (179). IL-6 supports proliferation of synovial 
fibroblasts, since they do not express CD126 this response is likely to be mediated by 
transsignaling.  Synovial fibroblasts themselves are a major source of IL-6 in the synovium 
therefore they may provide a positive feedback mechanism. 
IL-6 has been pointed out as a factor in cartilage destruction in the joint. Osteoclasts are major 
mediators of joint erosion and IL-6 has been demonstrated to promote differentiation towards 
this cell type (180). 
The importance of IL-6 transsignaling in RA pathology was highlighted by Nowell M. A et 
al. They demonstrated the presence of high levels of sIL-6R in the SF of RA patients 
compared to patients with Osteoarthritis. The major source of sIL-6R comes from shedding 
from cell membranes. To further highlight the importance of transsignaling they showed that 
IL-6-/- mice that resisted the development of AIA were susceptible to the disease when 
reconstituted with sIL6-IL6 complexes. Furthermore, they demonstrated that transsignaling is 
involved in the recruitment of leukocytes via chemokine CCL2. The addition of the sIL-6R 
antagonist, spg130, to AIA mice model blocked the development of the disease (181). 
1.5.8 IL-10 and RA 
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IL-10 is present in the SF and ST of RA patients. RA was demonstrated by 
immunohistochemistry in the joint by (reviewed in (182)). IL-10 mRNA was also 
demonstrated in RA and OA patients (182). Sources of IL-10 include T cells and monocytes 
(reviewed in (183). It seems like IL-10 plays an anti-inflammatory role as  neutralizing 
endogenous production of IL-10 in synovial membrane cultures results in a dramatic increase 
of TNF-α and IL-1β, while the addition of rIL-10 to the same cocultures results in decreased 
production of TNF-α and IL-1β, interestingly the levels of IL-6 are not affected (reviewed in 
(182)). However, the presence of IL-10 has been associated with exacerbation of the disease. 
Lard and colleagues conducted a study looking at the relation of IL-10 promoter 
polymorphism and RA. They demonstrated that there was an association between the -2849 
IL-10 promoter polymorphism  which causes high  IL-10 production was correlated with a 
high level of joint destruction in RA (184). Another study compared synovial membrane 
mRNA levels of various cytokines with disease progression, and demonstrated that the 
cytokine most closely associated with damage was IL-10 (185). With an anti-inflammatory 
function of IL-10 in mind, it was tested in a clinical trial as a treatment for Rheumatoid 
arthritis and. Even though IL-10 did not cause major toxicity the patients did not show 
significant improvement (reviewed in (186)). 
1.6 Cytokine targeting therapies of RA 
The etiology of RA is not very well understood; therefore it is very difficult to develop a 
curative treatment. All treatments available to date aim to minimize the signs and symptoms 
of the disease. An important target is to delay the bone erosion that leads to loss of joint 
function and eventually to disability. It is now understood that it is crucial to start treatment as 
early as possible in the disease process, the sooner the treatment begins the better the likely 
outcome is for the patient.  Established treatment regimes for RA include glucocorticoids and 
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disease modifying antirheumatic drugs (DMARD) such as methotrexate and sulfasalazine 
(reviewed in (187)). 
More recently, a new class of drugs has been developed based on our increasing 
understanding of the cell types and cytokines involved in the pathophysiology of RA. This 
group of drugs, termed “biological”, contains monoclonal antibodies specific for cytokines 
and cell populations and soluble receptors that can prevent cell-cell or cell-cytokine 
interaction. Combinations of TNFα blocking antibodies or soluble receptors with 
methotrexate have considerably improved the treatment of severe RA (reviewed in (188)). 
1.6.1 B cell depletion   
B cells are well known to contribute to RA pathology. Antibody-secreting B cells are 
responsible for the production of RF in RA, and in turn RF contributes to the disease by 
triggering the formation of immune complexes that lead to complement activation, leukocytes 
infiltration and the formation of membrane attack complex (189,190) . B cells also play a role 
as APC, they process and present antigen to T cells in RA and as a consequence T cells 
proliferate and act as pro-inflammatory agents. Furthermore, B cells contribute to RA 
pathology by the secretion of cytokines such as IL-4 (191). A monoclonal antibody has been 
developed against a B cells transmembrane proteins expressed in mature B cells known as 
CD20 (192). This drug, Rituximab, causes B cell death by three different mechanisms. It 
promotes B cell apoptosis,  a Rituximab-CD20 complex activates complement leading to the 
formation of the membrane attack complex which causes B cell lysis (193) and it induces cell 
mediated cytotoxicity  (194). Several clinical trials using rituximab alone or in combination 
with other drugs have shown that this compound is very beneficial for the treatment of RA as 
well as not showing any significant toxicity (reviewed in (195)). Although the response to 
rituximab is very satisfactory, clinical relapses have been observed after treatment, these 
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relapses seem to be associated with the reappearance of B cells in the bloodstream (reviewed 
in (196)). B cells may survive rituximab treatment by several mechanisms. For example, 
levels  of BLyS, a B cell anti-apoptotic can be increased upon B cell depletion, supporting the 
repopulation of the B cell pool. BLyS has also been suggested to counteract the cytotoxic 
effect of rituximab (197)  (reviewed in (195)). 
1.6.2 TNF targeting therapies 
TNF-α is a critical cytokine with a role in adaptive immune responses and homeostasis. It is 
generated by several cell types including monocytes, T and B cells (198). The expression of 
TNF-α is induced by several stimuli including: TLR stimulation, various cytokines, viral 
agents and neoplasmic transformation. TNF-α triggers the activation of immune cells such as 
NK cells, Cytotoxic T cells and PMN cells, it also stimulates proinflammatory cytokine 
production, it has an role in cartilage breakdown as it promotes osteoclastogenesis and 
inhibits collagen synthesis (199). The contribution of TNF-α to RA pathology has been 
highlighted by several studies using murine models for RA. TNF-α overexpressing mice 
spontaneously develop a systemic inflammatory condition affecting the joints that resembles 
RA (200).  
Currently four anti-TNF drugs are in clinical use: infliximab, etanercept, adalimumab and 
Certolizumab pegol. Infliximab is a monoclonal antibody against TNF-α, it has a humanized 
constant region and a murine variable region. It binds soluble and membrane-bound TNF-α, 
neutralizing their effects. Serious adverse reactions have not been reported but some patients 
seem to make antibodies against this drug lowering its efficacy. Etanercept is a recombinant 
form of the TNF receptor 2 obtained by recombinant DNA technology. This drug binds both 
soluble TNF-α and TNF-β blocking their biological action, antibodies against this drug have 
also been observed in about 10% of the patients (201,202). Adalimumab is a human 
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monoclonal antibody that specifically targets TNF-α both in soluble and bound form. (202). 
Certolizumab pegol is a humanized Fab fragment of an anti TNF-α antibody coupled to 
polyethyleneglycol (203) 
1.6.3 IL-10 as a therapeutic agent. 
IL-10 has a very important role in the prevention of autoimmunity. This has been 
demonstrated using IL-10 deficient mice in autoimmune models. In all murine models of 
autoimmune disease tested, disease is exacerbated in the absence of IL-10. The observations 
of the anti-inflammatory role of IL-10 formed the scientific basis for its use as a therapeutic 
agent to treat autoimmune diseases (reviewed in (204)). 
Therapeutic use of recombinant IL-10 has been tested in patients with a range of autoimmune 
disease such as psoriasis, Crohn’s disease or RA. rIL-10 treatment may be beneficial when 
used in small doses if delivered locally to the site of inflammation. When higher doses of rIL-
10 were used to treat RA it resulted in an enhanced inflammatory response (79). It was 
observed by van Roon and colleagues that IL-10 treatment caused the upregulation of Fc 
gamma receptor on monocytes/macrophages in IL-10 treated RA patients, it seems that Fc 
gamma receptor upregulation may counteracts the anti-inflammatory action of IL-10 possibly 
by triggering a proinflammatory response to immune complexes (205). 
1.6.4 IL-6 as a therapeutic target for RA 
It has been demonstrated that IL-6 plays an important role in the development of RA both by 
contributing with its proinflammatory actions. Animal models have also shown that the lack 
of IL-6 results in failure to induce RA-like disease or cause diseases with less severity and 
milder symptoms. IL-6 actions are caused by both direct signaling through its receptor or via 
transsignaling. So it is logical to think that interfering somehow with the actions of IL-6 you 
may be able to ameliorate the symptoms of RA.  
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A humanized anti-IL-6R monoclonal antibody is known commercially as Tocilizumab (206). 
Anti-IL-6R is able to block IL-6 signaling mediated by membrane bound IL-6R or via 
interactions between IL-6/sIL-6R that lead to transsignaling (reviewed in (207)). 
Administration of anti-IL6R antibody led in phase I clinical trial to reduced levels of CRP and 
SAA that reach normal levels, suggesting that IL-6 signaling was required for the 
overproduction of these protein in RA (49,208). Since then different clinical trials have 
demonstrated the beneficial effects of IL-6 receptor blocking therapy. It has been shown to 
improve patients’ outcomes including a substantial delay in joint erosion. It has also been 
tested in combination with other anti-rheumatic drugs such as methotrexate also leading to 
very positive results. No major adverse reactions have been described, however some 
moderate changes in cholesterol levels and in serum liver enzymes have been described 
following treatment with this drug (reviewed in (207)). Anti-IL-6R prevents neutrophil 
adhesion and joint damage caused by neutrophil release of proteolytic enzymes and ROS 
intermediates, it prevents osteoclastogenesis which in turn prevent bone reabsorption, it also 
prevents proteoglycan synthesis and pannus formation (reviewed in (209). Anti-IL-6R 
normalizes Amyloid levels and suppresses acute phase reactions so it is important to monitor 
patients under this treatment as they can be at risk of infection. Another possible adverse 
effect is the rise in cholesterol levels but cardiovascular complications have not been reported 
so far. Importantly IL-6R blocking does not loose its efficacy over time unlike other 
biological treatments such as anti-TNF (reviewed in (210) 
1.7 RA therapies targeting T cells.  
The association of RA with specific MHC haplotypes suggests a role for T cells in RA 
pathophysiology. They are present in high numbers in the synovium and their interaction with 
other cell types is thought to be driving inflammation. Several approaches to T cell therapy 
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have been used over the years. Anti-CD4, anti-CD5 and anti-CD52 antibodies have been used 
to deplete T cells; this therapeutic approach has had a transient effect that ends with the 
repopulation of autoreactive T cells. Autologous stem cell transplants following ablation of 
the bone marrow has been used experimentally. It is associated with a considerable risk to the 
patient and is mostly used as a last resort in patients with treatment resistant SLE and 
scleroderma. Although an improvement is observed in these patients they often relapse when 
the synovium is repopulated with naïve T cells (211). 
Abatacept is a biological that blocks costimulation following TCR engagement, interferes 
with T cell activation. This treatment has been successfully used in clinical trials on  RA 
patients (reviewed by (212). 
  
1.8 Project rationale 
The role of T cells in the pathogenesis of rheumatoid arthritis is not very well understood and 
remains subject of controversial discussion. It has been proposed that the role of T cells 
changes during the progression from early to established stages of rheumatoid arthritis. 
Antigen specific activation of T cells may occur early, while in established disease 
mechanisms independent of cognate interaction take over. One of the questions we wanted to 
address was in this project was whether such a change is reflected in differences in expression 
of activation markers on infiltrating T cells. 
Previous work in our laboratory has shown that there is a change in the profile of cytokines 
detectable in the synovial fluid of patients. Intriguingly, we detected an increased level of Th2 
cytokines IL-4 and IL-13 in the SF of very early RA patients. With iNKT cells being 
described as a source of IL-4 and IL-13, we were interested to examine whether these cells are 
specifically accumulated in the very early phases of RA. In addition, the transient but 
cytokine profile seen in early RA suggest that RA pathophisiology could be different in very 
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early stages compared to later stages. So we hyphothesised that presence of iNKT cells and T 
cell activation status varies between very early stages of RA and established RA. 
IL-6 plays an important role in the regulation of T cell responses. It affects differentiation into 
Tregs and Th-17 cells and can also act as a survival factor. We hypothesized that T cells 
infiltrating the Rheumatoid Joint can respond to IL-6 via direct signaling and transsignaling. 
 In this study, we investigated how the responsiveness of T cells in different compartments of 
the rheumatoid joint is regulated. In particular, we were interested in dissecting the expression 
of the two components of the IL-6 receptor, CD126 and CD130, in the synovial tissue, 
synovial fluid and peripheral blood of patients with RA. Having established that there is a 
difference in the expression of CD130 in T cells found in these three compartments, we 
examined the biological consequences of differential CD130 expression and possible 
mechanisms that regulate its expression in the synovium.  
1.9. Project aims. 
• To investigate the levels of iNKT cells in PB and SF of very early RA, very early 
arthritis and established RA compared to healthy controls. 
• To investigate the activation status of T cells from PB and SF from the same groups of 
patients and controls. 
• To investigate the level of expression of CD126 and CD130 on CD4 T cells from PB, 
SF and ST of RA patients. 
• To determine the biological consequence of the differential expression of CD126 and 
CD130 on T cells from SF and ST of RA patients. 
• To determine how CD126 and CD130 expression is regulated. 
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Chapter 2. 
 MATERIALS AND METHODS 
 
2.1 Patients 
We collected PB and SF samples from two groups of patients: patients with established RA as 
categorized by the 1987 ACR criteria and patients recruited from the Birmingham Early 
Arthritis Clinic, this group of patients was seen at the clinic within the first three months of 
symptoms. Within 18 months of presentation these patients were classified as having RA, 
resolving arthritis, or chronic arthritis other than RA. Informed consent was taken and ethical 
approval was obtained from the local ethical committee. Patients were not on biological 
treatments although some were on disease modifying drugs (DMARD). ST was obtained from 
RA patients, undergoing joint replacement surgery. Further information regarding the 
patients’ age, gender, disease duration, CCP status, disease activity and drug regime can be 
found in the attachment. 
 
2.2 Isolation of PBMCs by density gradient centrifugation 
 
Peripheral venous blood was collected from patients and healthy volunteers in tubes 
containing 10 U/ml of heparin (Multiparin r, Product License Authorization holder CP 
Pharmaceuticals, Ltd, Ash Road North, Wrexham, UK). The blood was gently mixed to 
ensure an even heparin distribution. The required volume of blood was mixed with an equal 
volume of RPMI1640 (Sigma), 2mM Glutamine 100U/ml Penicillin and 100 µg/ml 
Streptomycin. 2 ml of Ficoll-Paque™ PLUS (GE Healthcare Bio-Science, Uppsala, Sweden) 
were dispensed into 12 ml tubes, then 10 ml of RPMI diluted blood were slowly pipetted in an 
angle on top of the Ficoll layer. All tubes containing ficoll and diluted blood were centrifuged 
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at 220 g for 30 minutes at 20ºC with no brake. Subsequently a layer of PBMCs located above 
the ficoll was extracted extracted carefully using a fine plastic Pasteur pipette; the PBMCs 
were transferred into a 25ml tube. The tube was filled up with RPMI up to the 25 ml mark and 
centrifuged again at 1200 rpm at 20C for 8 minutes. After centrifugation the supernatant is 
discarded, and the cells were washed again. At this stage cells may be counted in a 
haemocytometer. PBMC’s obtained were used for several experiments including the isolation 
of CD4 T cells. 
Plasma 
Leukocytes and 
platelets 
Red Blood Cells 
 
 
 
Figure 7 : Schematic representation of a tube following density gradient centrifugation. The figure 
shows the three layers found following centrifugation, plasma, leukocytes and red blood cells. 
51 
 
 
2.3 Isolation of CD4 T cells by cell-sorting from PBMCs and STMCs 
 
PBMC’s and STMCs are obtained from PB by Ficoll density gradient centrifugation or by 
mechanical degradation of ST followed by Ficoll gradient centrifugation. PBMCs or STMCs 
are resuspended in 300µl of an antibody cocktail prepared in PBS 2%BSA. Antibodies used 
are shown in the following table: 
Antibody Dilution 
CD4 Tricolor (Caltag) (1:50) 
CD11b Fitc (ImmunoTools) (1:20) 
CD11c Fitc (ImmunoTools) (1:20) 
 
 
Cells are incubated for 30 minutes on ice and then washed twice by adding 1ml PBS 2%BSA 
and spinning down at 220 g for 4 minutes at 4C. After the washes cells are resuspended in 
500µl PBS 2% BSA and then filtered into a FACS tube. An irrelevant control and 
compensation tubes are set up. The cell suspension is run though the cell sorter (Mo Flowtm). 
A gate is set around the lymphocytes in the FS/SC window. CD4 positive, CD11b and CD11c 
negative lymphocytes are collected into a fresh FACS tube containing 500µl of PBS 2%BSA. 
Cells are centrifuged, the supernatant is discarded and the cells are resuspendend in RPMI 
BSA 1%, GPS 1%, HEPES 1% at a concentration of 5 million cells per ml. Sorted CD4 T 
cells will be used to study the expression of CD126/CD130 by flow cytometry after various 
treatments. 
2.4 Isolation of CD45RO CD4 positive T cells T cells by cell-sorting from  
 
PBMCs 
 
PBMCs and STMCs are obtained from PB by density gradient centrifugation or by 
mechanical degradation of ST followed by density gradient centrifugation. PBMCs or STMCs 
are resuspended in 300µl of an antibody cocktail prepared in PBS 2%BSA. Antibodies used 
are shown in the following table: 
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Antibody Dilution 
CD4 Tricolor (Caltag) (1:50) 
CD3Pe (ImmunoTools) (1:20) 
CD45RO Fitc (DAKO) (1:40) 
 
 
Cells are incubated for 30 minutes on ice and then washed twice by adding 1ml PBS 2%BSA 
and centrifugation at 220 g for 4 minutes at 4C. After the washes cells are resuspended in 
500µl PBS 2% BSA and then filtered into a FACS tube. An irrelevant control and 
compensation tubes are set up to control that there is no unspecific staining and to subtract 
spectral overlap of the individual fluorochromes. The cell suspension is run though the cell 
sorter (Mo FlowTM). A gate is set around the lymphocytes in the FS/SC window. CD4 
positive, CD3 positive and CD45RO positive lymphocytes are collected into a fresh FACS 
tube containing 500µl of PBS 2% BSA. Cells are centrifuged, the supernatant is discarded and 
the cells are re-suspended in RPMI BSA 1%, GPS 1%, HEPES 1% at a concentration of 5 
million cells per ml. Sorted CD45RO positive CD4 T cells will be used to study the 
expression of CD126/CD130 by flow cytometry after various treatments and to study the 
effect of HUVEC transmigration on the expression of CD130. 
2.5 Processing of ST samples to obtain STMCs. 
ST is brought to the laboratory after surgery. The tissue is placed in a Petri dish with ca 10ml 
RPMI 1640. ST is cut in ca 1mm3  pieces using a sterile scalpel. The tissue fragments are 
transferred into a 50ml tube using a 25ml pipette and the tube is filled with RPMI (2nM 
EDTA). Cells are then pelleted at 220 g for 8 minutes. After centrifugation the supernatant in 
discarded and tissue is resuspended in 20ml RPMI. The tissue is then transferred into a plastic 
bag produced to fit into the stomacher. The bag is heat-sealed to avoid spillage. The tissue-
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fragments are mechanically processed in a Stomacher 400 Circulator for 5 minutes at 230 
rpm. Processed tissue is filtered into a falcon tube. The filtered solution is ficolled to obtain 
STMCs. STMCs obtained from ST are used for various experiments.   
FS 
 
S
CD4 
 
 
CD3 
 
 
 
  
 Figure 8.  Processing of ST to obtain STMC. Tissue from Joint replacement operations is cut into 
small pieces and then processed in a Stomacher 400 Circulator to obtain a cell suspension from 
which we obtain STMCs via density gradient centrifugation. 
 
2.6 Flow cytometry 
The flow cytometers used in our experiments were an EPICS XL Flow Cytometer from 
Beckman Coulter and a Cyan ADP 9 color from DAKO. The expression of cellular surface 
markers was detected using direct labeled antibodies directed to those particular markers. The 
labels used included PE, Fitc, PeCy5 and PeCy7. Bound labeled antibodies were detected by 
excitation using a 488 nm argon laser. Every experiment was calibrated using Flow-setTM 
Flurospheres standardization reagents (Beckman Coulter and Cyan). Compensation was used 
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for all colors to make sure each laser only stimulates the particular fluorescent molecule that 
is supposed to and not others. Isotype species and concentration matched controls antibodies 
were used to determine the level of background staining. 
Flow cytometry data was analyzed using WinMDI software (version 2.8, Scripps  
Research Institute, La Jolla, CA) and SummitTM. 
2.6.1. Three-color flow cytometry to quantify iNKT cells and determine T cells 
activation status. 
PB and SF are collected from our patients and consented healthy donors. 10 U/ml of 
Hyaluronidase are added to the SF. SF is then incubated at 37ºC for 20 minutes to reduce 
viscosity.  
Subsequently 2ml of SF and 2 ml of PB are washed with 1ml of MACS buffer (PBS, 0.5% 
BSA, 2nM EDTA, pH 7.2). The supernatants are discarded and 50 µl of SF packed cells and 
PB packed cells are pipetted into tubes for immunostaining. 50 µl of the required antibody 
mixture at the appropriate dilution are added to the cells. Antibodies used and dilutions are as 
follows: 
 
• Irrelevant antibodies: IgG1Pe (1:20) (DAKO), IgG1Fitc (1:20) (DAKO) and 
CD3Pe/Cy5 (1:30) (ImmunoTools) 
• Compensation antibodies: CD4Pe (1:50) (BD biosciences), CD4Fitc (1:40) (BD 
biosciences),   and CD3Pe/Cy5 (1:30) (ImmunoTools) 
• 4 combinations of  anti- iNKTpe (1:15) (BD PharmingenTM ) and CD3Pe/Cy5 (1:30) 
(DAKO) with the following activation markers: CD25Fitc (1:5)(BD), CD69Fitc (1:25) 
(BD), CD71Fitc (1:200) (ImmunoTools) and HLA-DRFitc (1:100) (BD) . The anti-
iNKT antibody, isotype IgG1, k, it is a monoclonal antibody 6B11 which reacts with a 
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unique determinant in the CDR3 region of the invariant (Vα24-JαQ) TCR chain. Thus 
6B11 identifies a subset of all Vα24 positive T cells 
 
After 30 minute incubation on ice 1 ml of RBC Lysis buffer (NH4Cl Tris-HCL dH2O) is 
added to all tubes and incubated for 7 minutes at RT. Then cells are  
washed twice by adding 1 ml of MACS buffer and spinning down in the centrifuge at  
220 g for 6 minutes at 4º C. Finally the cells are resuspended in 500µl of ice-cold  
PBS. 
2.6.2. Three-color flow cytometry to determine the expression of CD130 and  
CD126 on freshly isolated CD4 T cells. 
CD4 T cells are FACS sorted from PBMC’s (as described in section 2.3) or isolated  
by negative selection using MACS beads (as described in section 2.2). CD4 T cells are 
resuspended in PBS 2% BSA at a concentration of 5 million cells per ml. 20µl of cell 
suspension are pipetted into a FCS coated well of a 96 well flexi-plate. The desired treatment 
is added to the cells; treatments, concentration and incubation condition are described in the 
following table: 
 
Treatment Concentration Incubation conditions 
Medium (RPMI) Undiluted 0h, 1h, 3h, and 18h at 37ºC 
IL-6 (Pepro Tech) 10ng/ml 1h at 37ºC 
Anti-IL6R antibody  1ug/ml 1h on ice 
SF from RA patients Undiluted 1h at 37ºC 
 
In seven experiments two treatments are used in combination, first a blocking α-IL6R 
antibody is added to the cells and after incubation IL-6 or SF are added without washing off 
the previous treatment. Following a second incubation period, cells are washed and 
resuspended in 50µl of the required antibody or antibody mixture at its optimum dilution; the 
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antibodies used vary depending on how CD4+ T cells are isolated. If cells are obtained by 
negative selection the antibodies used are as follows: 
• Irrelevant antibodies: IgG1PE (1:20) (DAKO), IgG1Fitc (1:20) (DAKO) and 
CD3Pe/Cy5 (1:30) (ImmunoTools) 
• Compensation antibodies: CD4PE (1:50), CD4Fitc (1:40) and CD3PE/Cy5 (1:30) (all 
from ImmunoTools) 
• A mixture of CD4Fitc (1:40) and CD3PE/Cy5 (1:30) (both from ImmunoTools) 
combined with either CD126PE (1:2.5) (Immunotech) or CD130PE (1:5) (BD 
PharmingenTM ). 
In the case where CD4+ T cells were FACS sorted the cells are already stained with CD4-
Tricolor so the antibodies used are: 
• Irrelevant antibodies: IgG1PE (1:20) (DAKO), IgG1Fitc (1:20) (DAKO) and 
CD3Pe/Cy5 (1:30) (ImmunoTools) 
• Compensation antibodies: CD4PE (1:50), CD4Fitc (1:40) and CD3PE/Cy5 (1:30) (all 
from ImmunoTools) 
• CD126PE (1:2.5) (Immunotech) or CD130PE (1:5) (BD PharmingenTM) 
In both cases compensation tubes are set up using PBMCs rather than sorted CD4 positive 
cells. After incubation for 30 minutes on ice the cells are washed twice by filling up the wells 
with PBS 2% BSA and centrifuging the plate at 220 g for 4 minutes at 4ºC, then they are 
transferred to FACS tubes containing 500µl of ice-cold PBS. Irrelevant controls and 
compensation tubes were included. Cells are read by flow cytometry. 
2.6.3 Four color flow cytometry to investigate the expression of CD126 and CD130 on 
CD45RO positive CD4 T cells from PB, SF and ST. 
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PBMCs and SFMCs are obtained by density gradient centrifugation. STMCs were obtained 
processing ST using mechanical disintegration with a Stomacher 400 Circulator as described 
in section 2.4 and then by ficoll gradient centrifugation. PBMCs, SFMCs and STMCs were 
stained with 50ul of the antibodies shown in the following table: 
Antibody Company Dilution 
Anti-CD126Pe or anti-
CD130Pe 
Immunotech and BD 
Pharmingen™ 
respectively  
1:2.5 and 1: 5 respectively 
Anti-CD3PeCy5 Immunotools 1:15 
Anti-CD4PeCy7 BD Pharmingen™ 1:10 
Anti-CD45ROFitc DAKO 1:40 
 
The cells were incubated with the antibodies for 30 minutes on ice, and then cells were 
washed with PBS/BSA twice and resuspended in 500ul of PBS/BSA. Cells were analyzed 
using a DAKO Cyan flow cytometer. 
2.7 Cytokine CD4 T cell treatments.  
CD4 T cells are obtained by ficoll gradient centrifugation of PB and subsequent FACS sorting 
for CD4 cells. CD4 T cells are resuspended in RPMI with 5% HEPES, 5% GPS and 5% BSA 
at a concentration of 1 million cells per ml. The following cytokines are added to cells: 
• IL-6 (10ng/ml) 
• IL-23 (10ng/ml) 
• RANTES (10ng/ml) 
• MIP1-α (10 ng/ml) 
• IFN-γ (10ng/ml) 
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• TNF-γ (10ng/ml) 
• IL-10 (10ng/ml and 100ng/ml) 
• IL-17 (10ng/ml) 
• IL-15 (10ng/ml) 
• SDF (40ng/ml) 
Cells were treated with these cytokines for 6h at 37ºC. After treatment cells were washed 
twice in PBS/BSA. Cells were subsequently used for FACS staining or RNA extraction. 
2.8 PBMC, SFMC and STMC treatment. 
PBMCs, SFMCs, and STMCs were obtained from density gradient centrifugation of PB, SF 
and processed ST. The cells were resuspended in RPMI (with HEPES, GPS and 1% BSA) at a 
concentration of 5 million cells per ml. 20µl of cell suspension were pipetted into the wells of 
a flexiplate previously coated with FCS. Cells were treated at 37ºC for 15 minutes with hyper 
IL-6 (25ng/ml) IL-6 (1 µg/ml), sIL-6R (10 ng/ml), IL-2 at (50 U/ml) and IFNβ. Following 
treatments were washed with 100 µl of TBS. Cells were then ready for FACS staining. 
2.9 Tissue sectioning 
 
Synovial tissue sections are cut from ST surgically removed from RA patients which is first 
snap frozen in liquid nitrogen and then stored at -80ºC. The sections are 5 microns in depth; 
each section is deposited on a 4 spot glass slide. The sections are allowed to dry under a fan 
for 2-3 hours and then they are fixed in acetone for 20 minutes at 4ºC. After fixation the 
sections are stored at -80ºC in individual plastic bags. 
 
2.10 Immunohistochemistry Staining 
 
Immunofluorescence allows us to visualize the expression of cellular molecules in synovial 
tissue sections stained with primary antibodies against these molecules and secondary 
antibodies conjugated to fluorescent markers that specifically bind to the primary antibodies. 
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The fluorescent markers are excited by several lasers (351/364, 488, 543 and 633 nm lasers) 
using a Zeiss LSM 510 confocal scanning microscope (Carl Zeiss, Jena, Germany). This 
translates into images in which targeted cell molecules are seen in different colors. Confocal 
microscopy is an imaging technique used to obtain high resolution images. A key feature 
of confocal microscopy is its ability to produce blur-free images that are taken point-by-point 
and reconstructed with a computer. A digital camera is attached and allows obtaining digital 
pictures of stained tissue. Digital photos are later analyzed using the Zeiss LSM Image 
browser software. 
Tissue sections are taken out of the freezer and allowed to reach RT inside the plastic bag 
where they were stored. Once at RT tissue is re-hydrated by adding 2-3 drops of PBS on top 
of each section. PBS is removed with a fine Pasteur pipette and 2-3 drops of Image-iTTM FX 
Signal Enhancer (Molecular Probes, Invitrogen detection technologies) are added to each 
section. The sections are incubated for 30 minutes at RT in a humid chamber. Following this 
incubation the Image-iTTM FX Signal Enhancer is removed and without washing, 100µl of 
the primary antibody mixture or matched isotype irrelevant controls is pipetted on top of the 
tissue sections. Primary and isotype control antibodies used are as follows: 
• Primaries: CD3Biotin (1:20) (BD), CD4 (OKT4) (1:50) (University of Birmingham) 
and CD130 (1:50) (Santa Cruz), anti-IL-6 (1:10)(R&D Systems), anti-IL-10 (1:50) 
(R&D Systems), CD157 (1:50), CD19 (1:50) 
• Isotype controls: Mouse IgG1, mouse IgG2b and rabbit IgG (all from DAKO)  
 After 30 minute incubation step at RT in a humid chamber the sections are washed for 10 
minutes in PBS. 100µl of diluted secondary antibody is used to reveal the bound primary 
antibody. Secondary antibodies used include: 
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• Anti mouse IgG2b-Cy5 (1:250) (Southern Biotechnology), anti-mouse IgG1-Fitc 
(1:50) (Southern Biotechnology) and anti-rabbit IgG-Alexa Flour 594 (1:200) 
Molecular Probes, Invitrogen). 
 Following an incubation of 30 minutes at RT in a humid environment the tissue is washed for 
15 minutes in PBS. After washing the tissue is dipped for 2 minutes in Hoechst nuclear stain 
(Hoechst bisbenzimide 332382, 10mg/ml with 0.05% azide) excess of nuclear stain is washed 
off in PBS, and slides are mounted by adding a drop of DAKO mounting media to each spot 
and placing a coverslip onto the slide. 
2.11 Quantification of CD130 signal on CD4 T cells within and outside the perivascular 
infiltrates in ST sections from RA patients. 
Confocal pictures were taken of ST sections stained with anti-CD3, anti-CD4 and anti-CD130 
Images were further analyzed using the Zeiss LSM Image software. First the software 
identifies double positive cells for CD3 and CD4 by multiplying positive pixels for the two 
channels we were able to create a new channel (and give it a new color, yellow) that identified 
CD3/CD4 positive cells. A gate was drawn around the cell membrane of individual CD3/CD4 
positive cells, the number of positive pixels for CD3CD4 and for CD130 and the area gated 
around was given by the program. Finally we obtained number of positive pixels per 
micrometer square. 
2.12 FACS staining for phosphorylated STAT3. 
25 µl of TBS plus 50 µl 3% formaldehyde in PBS was added to cytokine treated mononuclear 
cells were incubated for 10 minutes at RT. Cells were subsequently washed with 100 µl TBS. 
50 µl of CD4Tricolor and CD45ROPE was added to the cells and cells were incubated for 20 
minutes at RT. Cells were then washed with 100 µl TBS. After washing the cells are 
resuspended in 75 µl of TBS and 150 µl of ice-cold absolute methanol were added to the cell 
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suspensions, the cells are incubated in methanol for 10 minutes at 4ºC. Following incubation 
cells were centrifuged and washed with 150 µl of TBS 2% BSA and left overnight. 50 µl of 
Fitc conjugated anti-phospho-STAT3 (BD) (1:5) antibody was added to the cells and cells 
were incubated for 30 minutes at RT. Cells were then washed twice in TBS 2% BSA and 
resuspended in 400 µl of TBS 2% BSA and analysed by flow cytometry.  
2.13 RNA extraction.  
The RNeasy® Mini Kit (Qiagen) was used for all RNA extractions.The RNeasy® Mini Kit  is 
based on a column containing a silica-based membrane to which up to 100µg of RNA can 
bind in the presence of the appropriate high-salt containing buffer. High-quality RNA is then 
eluted in 30–100 μl water. 100,000 to 200,000 treated cells were resuspended in 350µl of 
RLT buffer; the RLT buffer contains highly denaturing guanidine-thiocyanate, which 
inactivates RNases. The cells were then kept at -80ºC for at least 30 minutes, but at several 
occasions the cells were stored in these conditions for several days. When the cell suspension 
defrosted, 1 volume of 70% ethanol was added. Subsequently 700µl of the cells suspension 
were transferred to an RNeasy mini column, the column was places in a 2 ml collection tube. 
The cells were centrifuged at >10,000 rpm for 15 seconds, the flow through was discarded. 
700µl of RW1 buffer were added to the column, the column was then centrifuged at >10,000 
rpm for 15 seconds, the flow-though was discarded. The later step was repeated, then 500 µl 
of RPE buffer were added to the column which was subsequently centrifuged at > 5000 g for 
15 seconds, the flow through was discarded. 500 µl of RPE buffer were added to the column 
to was membrane bound RNA and this was centrifuged at >10,000 rpm for 2 minutes, the 
flow though was discarded and the column was places in a clean collection tube, 50µl of 
RNase free-water was added to the column an the column was centrifuged at >10,000 rpm for 
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1 minute. Finally the column was discarded and the flow through containing the RNA was 
stored at -20ºC for future use. 
2.14 Reverse transcription of RNA to produce cDNA.  
5µg of RNA were transferred into to a PCR tube. 1µl of oligo (dT) 12-18 primer (1µg/ml) 
was added and finally the volume was made up to 17µl with RNA-free water. The mixture 
was heated in a thermocycler to 65ºC for 10 minutes. After this first incubation the mixture is 
allow to cool down on ice. Subsequently a mixture containing: 8µl 5x first-strand buffer 
(250mM Tris-HCl, pH 8.3 at room temperature;3.75 mM KCl, 15 mM MgCl2),, 4µl of 0.1M 
DTT, 2µl of each dNTP(10mM), 2µl of Superscript II (200U/µl) and 1µg of water was added 
to the tube which was then incubated at 42ºC for 2 hours. After incubation resulting cDNA is 
stored at -20ºC for further use. 
2.15 cDNA purification. 
All cDNA purifications were performed using NucleoSpin® Extract II kit (Macherey-Nagel). 
2 volumes of NT buffer were added to 1 volume of unpurified cDNA. A NucleoSpin® 
Extract II column was placed in a collection tube and then loaded with the sample, the column 
was centrifuged at 11,000g for 1 minute. The flow through was discarded and 600µl of NT3 
buffer were added to the column. After a 1 minute centrifugation at 11,000 g the flow though 
was discarded and the column was centrifuged again for 2 minutes at 11,000 g for to eliminate 
all excess of NT3 buffer. Subsequently the column was placed in a clean collection tube and 
the purified cDNA was eluted in 50 µl of elution buffer. Purified cDNA was stored at -20ºC 
2.16 Real Time Polymerase Chain Reaction (RT-PCR). 
All RT-PCR reactions were performed in a Stratagene Mx3000P™ RT-PCR machine. A 
mixture containing 1µl of GP130 Probe, 1µl GP130 Forward primer (5` 
CATTGGAAATGAAACTGCTGTGA 3`),1 µl of GP130 Reverse Primer (5` 
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GCTGCCATTCGTACCATGTACA3`), 0.5 µl of 18s probe, 0.2 µl of 18s Forward Primer (: 
5` GCCGCTAGAGGTGAAATTCTTG 3`), 0.4 µl of 18s Reverse Primer (5` 
CATTCTTGGCAAATGCTTTCG 3`), 12.5 µl of RT-PCR TaqMan® TR-PCR master mix 
(Applied Biosystems), 50 ng of cDNA and water to make up a volume of 25 µl. The plate 
containing the PCR mixtures was sealed and centrifuged then it was placed in the RT-PCR 
machine and this was set to do one cycle of 2 minutes at 50ºC, one other cycle of 10 minutes 
at 95ºC and 45 cycles of 15 seconds at 95ºC and 1 minute at 60ºC. 
2.16.1 RT-PCR Analysis. 
RT-PCR was analysed using the MxPro-Mx3000P software. The fluorescence (DR) was 
plotted against the number of cycles on a log scale. The baseline was set at fluorescence 50. 
The thresholds for 18s and CD130 fluorescence were set at the exponential phase of the 
fluorescence curve. The Ct values are obtained and exported to Excel (Microsoft office). The 
Delta Ct is calculating subtracting the 18s Ct to the CD130 Ct. The Relative Quantity of 
CD130 mRNA is 2-DCt 
2.17 Isolation of Human Umbilical Vein Endothelial Cells (HUVEC) cells and cell 
culture. Endothelial cells were isolated from the veins of fresh human umbilical cords using 
collagenase as previously described (213). The vein was cannulated at each end and washed 
through with PBS until all the blood was removed. Then 10ml of collagenase (1mg/ml) 
diluted in PBS was perfused through the cord until it was visible in both cannula. The cord 
was then incubated for about 20 minutes at 37oC. Then, the cord was massaged to loosen the 
cells. The cells were placed into two 15ml Falcon tubes by perfusing the cord with 30ml PBS, 
and then, the cells were centrifuged for five minutes at 500g. The isolated HUVEC were re-
suspended in HUVEC medium and were plated into 1% gelatin-coated T25 culture flasks 
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(Falcon), and cultured for about four to six days until confluent, the medium was changed 
every day to maintain the pH. 
When cells were confluent, the HUVEC medium was aspirated off and the HUVEC were 
bathed in 2mls EDTA (0.02%) for 1 minute. The HUVEC were then incubated with trypsin 
solution (2.5mg/ml) in a 2:1 ratio with EDTA. Using phase-contrast microscopy, visual exam 
determined when the cultured HUVEC had detached. At this point the reaction was stopped 
by adding 5mls of HUVEC medium. The contents of the T25 flask were transferred to a 15ml 
Falcon tube and spun at 500g for 5 minutes. The HUVEC were re-suspended in HUVEC 
medium, plated out and incubated at 37oC. These first passage HUVEC were plated onto low-
density 0.4μm pore polycarbonate Transwell filters, which were placed in matching plates 
(six or twenty-four well format; from BD Pharmingen and referred to as filters in future text). 
Seeding densities were chosen to yield confluent monolayers within 24 hours, and cultures 
were maintained for up to five days. Each experiment used first passage cells from a single, 
different cord. The isolation and culture of HUVEC cells was done by Dr. Helen MacGettrick. 
2.18 Transmigration of sorted CD45RO positive CD4 T cells through a monolayer of 
HUVEC cells 
First passage HUVEC were cultured on filters designed for 24-well Falcon plates for 24 days 
in a 5% CO2 incubator. HUVEC were stimulated for 24 hours with TNF and IFNγ (100u/ml 
and 10ng/ml respectively) after which, the medium in the lower chamber was replaced with 
fresh medium M199 (SAF Biosciences) + BSA, and medium in the upper chamber was 
replaced with PBL (2x106cells/ml in M199+BSA).Freshly FACS sorted CD4RO Positive 
CD4 Positive T cells were allowed to settle, adhere to, and migrate at 37oC for 24h. The 
experiment was stopped by transferring the filter into a fresh well. The PBL in the upper 
chamber were transferred to a fresh well and the filter was washed twice. The cells from the 
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washes were pooled with the upper sample and were taken to represent non-adherent PBL. 
The PBL in the lower chamber were re-suspended and washed with fresh medium. These 
were taken to represent the transmigrated PBL. The transmigrated cells and non transmigrated 
cells were collected in different tubes for further FACS staining. 
1.18.1 Flow cytometry to determine CD130 expression on CD45R0 positive CD4 T cells 
following HUVEC transmigration.  
CD45R0 positive CD4 T cells are obtained by FACS sorting from PBMCs. Sorted cells are 
places on top of a HUVEC monolayer and are incubated for 24h. Cells on top and under the 
HUVEC cells are collected in different tubes and used to determined CD130 expression via 
flow cytometry. CD45R0 positive CD4 T cells are stained with CD130PE (1:5) (BD 
PharmingenTM) for 30 minutes in a flexiplate. Cells are then washed and resuspended in 500ul 
of PBS/BSA and read in the flow cytometer. 
2.19 Statistical Analysis 
To analyze and compare data two non parametric statistic tests were used: the Kruskal Wallis 
test and the Mann Whitney tests. The Kruskall Wallis test is used for testing the equality of 
population medians between different groups. The Mann Whitney test is often used as an 
alternative to t test when the data are not normally distributed; this test also compares 
population medians of unpaired groups. The result of statistical tests applied is a P value, and 
when the P value is < 0.05 the difference in groups of data compared is statistically significant 
(214).  
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Results 
Chapter 3 
 
3. Expression of IL-6 receptor by T cells infiltrating the 
rheumatoid joint. 
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3.1 Introduction: 
The complete IL-6 receptor complex including both CD126 and CD130 chains is only 
expressed in only a few cell types such as leukocytes and hepatocytes. In contrast, CD130 is 
expressed ubiquitously (58). As I have previously explained IL-6 can initiate a signal through 
two distinct mechanisms: direct signaling and transsignaling. Transsignaling, when IL-6 
forms a complex with the soluble form of the IL-6R (IL-6/sIL6R) and this complex bind to 
CD130. Transsignaling allows IL-6 to signal to a wide array of cells that expressed CD130 
but not CD126. IL-6 transsignaling is important in inflammation as stromal cells of 
inflammatory sites are IL-6R negative and CD130 positive; therefore transsignaling mediates 
many of the IL-6 proinflammatory effects (reviewed in (58)). It is clear that IL-6 contributes 
to RA pathology as illustrated by the high levels of IL-6 found in RA SF and serum (181,215-
217), the promising results of blocking IL-6 in clinical trials in RA (208)  and the clear 
correlation of IL-6 level and joint damage (217). Some experimental work has shown that 
some of the effects of IL-6 in RA are mediated via trans-signaling (reviewed in (218)). IL-6 
deficient mice are resistant to AIA and reconstitution with IL-6 is not sufficient to trigger the 
disease, in the other hand disease symptoms do appear as you inject the mice with sIL-6/IL-6 
(reviewed in (218)). In addition IL-6 transsignaling promotes osteoclast formation in vitro 
(215), it triggers collagenase-3 secretion by osteoblasts and proteoglycan synthesis by 
chondrocytes contributing to joint destruction (219,220). 
In addition IL-6 has various important effects on CD4 positive T cells. IL-6 promotes CD4 T 
cells survival (50). IL-6 protects CD4 T cells from activation induced cells death (AICID) by 
downregulation of FasL (221). The expansion of antigen specific CD4 T cells is increased by 
IL-6 (222). In addition to support of survival and proliferation of CD4 T cells, IL-6 also 
modulates the differentiation of T cells into Th2 and Th17 cells (reviewed in (223)).    
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In the work shown in the following chapter we investigated the expression of both CD130 and 
CD126 in the different compartments of the rheumatoid joint and whether they respond to IL-
6 directly or via transsignaling.  
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3.2 RESULTS 
3.2.1 Divergent patterns of CD130 and CD126 expression in the different compartments 
of the rheumatoid joint.  
We investigated the expression of CD126 and CD130 on CD4 positive T cells from PB, SF 
and ST of RA patients to determine the expression of the two chains of the IL-6R in these 
three different compartments of RA patients.  
PBMCs and SFMCs were obtained by density gradient centrifugation. STMCs were obtained 
by mechanical degradation of ST followed by density gradient centrifugation. PBMCs, 
SFMCs and STMCs were stained with the appropriate fluorescent labeled antibodies and then 
read in the flow cytometer. An example of the staining in PB cells is shown in figure 9. The 
expression of CD126 was lower on CD4 positive T cells from RA SF and ST compared with 
paired PB samples. CD130 was expressed at low levels on CD4 T cells from RA SF when 
compared to PB. However, it was expressed at higher levels in ST CD4 positive T cells, at 
levels similar to those found in PB cells (Figure 10). The level of CD126 on SF and ST CD4 
T cells is significantly lower than their PB CD4 T cells (p<0.0001, Mann-Whitney test). The 
level of CD130 on CD4 T cells from SF is also statistically significantly lower than on PB 
CD4 T cells (p<0.005, Mann-Whitney test). Because most cells found in the rheumatoid 
synovium are primed CD45RO positive T cells we repeated the experiments comparing 
CD126 and CD130 expression on CD45RO positive CD4 T cells from ST, SF and PB. An 
example of the staining is shown in figure 9. We observed that the results were consistent and 
CD126 expression was low in SF and in ST, while CD130 was only low in SF but expressed 
at relatively high levels in ST (figures 10, 11 and 12). So we have defined 3 different 
phenotypes on CD4 positive T cells regarding IL-6R chain expression. CD126high CD130 
high in PB, CD126low CD130low in SF and CD126low CD130 high in ST. 
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Figure 9. CD130 on CD4 T cells from PB. Figure 9, from left to right shows: first a FACS 
plot of the FS/SS, secondly a FACS plot of CD3 versus CD4 straining and finally a histogram 
showing the CD130 expression on CD3/CD4 double  positive cells. 
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Figure 10. CD126 and CD130 expression on CD4 positive T cells in SF, ST and PB of RA 
patients.  Figure 10A shows the expression of CD126 on CD4 positive T cells obtained from 
SF, ST and PB samples from RA patients. Figure 10B shows the expression of CD130 on 
CD4 positive T cells of SF, ST and PB from RA patients. P values as calculated using a 
Mann-Whitney test. *** p<0.0001, ** p<0.005. 
SF: Synovial Fluid 
ST: Synovial Tissue 
PB (T): Peripheral Blood sample paired with a synovial tissue sample. 
PB (SF); Peripheral Blood sample paired with a synovial fluid sample. 
Ns: Non Significant 
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 Figure 11 Expression of CD130 on CD45RO positive CD4 positive T cells from RA SF, 
ST and PB. This graph shows on the left hand side FACS plots of PBMCs, SFMCs and 
STMCs stained for CD3, CD4, CD45RO and CD130. On the right, the three histograms show 
the expression of CD130 (black) on CD45RO positive CD3 positive and CD4 positive cells 
compared to an isotype control (white). 
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 n=4 for ST and PB (ST) 
n=6 for SF and PB (SF), SD 
Figure 12. CD126 and CD130 expression on CD45RO/CD4 double positive T cells. 
Figure 12A shows the level of expression of CD45RO positive CD4 positive T cells in SF, ST 
and PB.  Figure 12B shows the expression of CD130 on CD45RO positive CD4 positive T 
cells from SF, ST and PB from RA patients. Statistical significance of these differences was 
determined by Mann-Whitney test. * p<0.05. 
SF: synovial fluid 
ST: synovial tissue 
PB (ST): peripheral Blood paired with a synovial tissue 
PB (SF): peripheral blood paired with a synovial fluid sample 
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3.2.2 Tissue distribution of CD130 expression on CD4+ T cells 
So far we have demonstrated high expression of CD130 on CD4 positive T cells form RA ST 
and low expression in the SF compartment by flow cytometry. At this point we decided to 
investigate how CD130 expression is distributed on CD4 T cells localized in different areas of 
the synovium; the perivascular cuff and scattered throughout the tissue. To investigate this we 
took ST sections and we stained them with labeled anti-CD3, anti-CD4 and anti-CD130 
antibodies using immunohistochemistry techniques. Following staining we observed the 
tissue using confocal microscopy and took images of the stained tissue (Figure 13A). We 
analyzed the expression of CD130 on CD4 single cells clustering around the perivascular 
cuffs and single cells located distant from the cuffs. For this purpose we created a channel that 
identified double positive CD3 and CD4 (Figure 13B). Once CD4 positive T cells could be 
identified we drew a gate around the cell membrane of single CD4 positive T cells, with the 
CD130 channel switched off, then we switched it back on, and quantified CD130 expression 
measured as the number of positive pixels of intensities of above 20 per micrometer square.  
We found that CD130 expression in the perivascular cuff was high, at comparable levels to 
CD3/CD4 expression.  However CD130 expression was lower in cells localized distant from 
the perivascular infiltrate (Figures 14 and 15).  These observations suggest that a higher level 
of CD130 expression is found on CD4 positive T cells located in the perivascular areas in ST 
and that as CD4 positive T cells migrate away from the perivascular cuff the expression of 
CD130 may be gradually lost.  
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Figure 13. Confocal images of RA synovial tissue stained with anti-CD3, anti-CD4 and 
anti-CD130.  
Figure 13A shows a confocal image of RA synovial tissue stained with anti-CD3 (green), anti-CD4 
(blue) and anti-CD130 (red). In the centre of the image there is a perivascular cuff, shown with a white 
arrow, and some CD4 positive cells can be seen clustering around this perivascular cuff or located 
further away from it. Figure 13B shows the same image after being processed to identify double 
positive cells for CD3 and CD4. A new channel is created identifying all double positive cells and 
these cells can be seen in yellow. Several CD3, CD4 positive cells have been selected in this image 
from the perivascular cuff area and away from the cuff. Figure 13C is the same confocal image 
showing only CD130 signal. The circles show the level of CD130 expressed on the selected CD3CD4 
double positive cells within the perivascular cuff and at a distance from it. The arrow points at the 
perivascular cuff. 
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Figure 14. CD130 expression on CD4 positive cells located in the perivascular cuff and 
at a distance from the perivascular infiltrate.  
Graphs 14 shows the expression of CD130 on CD4 positive cell located within and away the perivascular cuff 
areas in the ST of four different RA patients. 
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CD3xCD4 expression versus 
CD130 in the perivascular cuff 
CD3xCD4 expression versus 
CD130 in non perivascular areas  
 
n=4 
* p value = 0.0286 
Figure 15. CD130 expression on CD3CD4 positive cells in perivascular cuffs and away 
from the perivascular cuffs.  
Figure 15. Shows the median expression of CD130 on 10 CD3CD4 positive cells located in the 
perivascular cuffs of four different patients. Figure 15B shows the median expression of CD130 on 10  
CD3/CD4 double-positive cells located distant to the perivascular cuffs of four different patients. The 
statistical analysis was performed using a  Mann-Whitney test. 
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3.2.3 Biological significance of high CD130 expression on CD4 T cells in the rheumatoid 
joint.  
CD4 T cells express low levels of CD126 and CD130 in SF but a different pattern of the IL-
6R expression is seen in the ST where CD126 expression is low but CD130 expression is 
high. As we found this different IL-6R pattern in SF and ST we decided to investigate 
whether there was a functional consequence to this expression pattern. We obtained PBMCs 
and SFMCs by ficoll gradient centrifugation and STMC by mechanical degradation of the 
tissue followed by ficoll gradient centrifugation. We treated cells with IL-6 and IL-6/sIL-6R, 
after treatment we stained the cells intracellularly for Phospho-STAT-3 at the Tyrosine 705. 
The presence of Phospho STAT-3 on CD4 positive T cells was then assessed by flow 
cytometry gating on the lymphocyte population. We looked at STAT-3 as readout of IL-6 
signaling as STAT-3 is phosphorylated following exposure of cells to IL-6. It is activated 
both by direct signaling and transsignaling. Example of the raw data can be seen in figures 16 
and 17. We found that CD4 positive cells from PB respond well to both IL-6 and IL-6/sIL-6R 
treatment and show high level of STAT-3 phosphorylation following treatment with either IL-
6 or sIL-6R/IL-6 (Figure 18). CD4 T cells from SF did not respond to IL-6 or IL-6/sIL-6R 
treatment and showed little STAT-3 phosphorylation (Figure 18). CD4 positive T cells from 
ST did not respond to IL-6 treatment, showing little STAT-3 phosphorylation, however, tissue 
CD4 T cells did respond to IL-6/sIL-6R treatments by STAT-3 phosphorylation (Figure 18). 
ST CD4 T cells were responsive to IFN-β (data not shown). 
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Figure 16. Expression of Phospho-STAT3 on CD4 T from PB and SF. On the left hand 
side the histograms show the expression of phospho-STAT3 on CD4 T cells from PB 
following treatment with medium, IL-6 and IL-6 plus sIL-6R. On the right hand side 
histograms show the expression of phospho-STAT3 on SF CD4 T cells following the same 
treatments. IL-6 was used at 10ng/ml for 1h and sIL-6R was used at 1000ng/ml for 1h together with 
IL-6 at 10ng for 1h. 
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Figure 17. Expression of Phospho-STAT3 on CD4 T from PB and ST. On the left side, the 
histograms show the expression of phospho-STAT3 on CD4 T cells from PB following 
treatment with medium, IL-6 and IL-6 plus sIL-6R. On the right side histograms show the 
expression of phospho-STAT3 on ST CD4 T cells following the same treatments. IL-6 was 
used at 10ng/ml for 1h and sIL-6R was used at 1000ng/ml for 1h together with IL-6 at 10ng for 1h 
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 n=4 
Figure 18. Level of STAT-3 phosphorylation on CD4 T cells from PB, SF and ST from 
RA patients following IL-6 and IL-6/sIL6R treatments.  
Graph 16  shows the levels of STAT-3 phosphorylation in CD4 T cells from patients with rheumatoid 
arthritis PB, SF and ST  treated with IL-6 and IL-6/sIL-6R. IL-6 was used at 10ng/ml for 1h and sIL-
6R was used at 1000ng/ml for 1h together with IL-6 at 10ng for 1h. SEM error bars p= 0.042 ( T 
Test) 
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3.3 DISCUSSION 
Our data suggests that expression of the two components of the IL-6 receptor, CD126 and 
CD130, is differentially regulated in different compartments of the rheumatoid joint. While 
both CD126 and CD130 expression is downregulated in CD4+ T cells that infiltrate the SF, in 
the ST, we observed CD4+-T cells with a low level of CD126 expression, but with CD130 
expression comparable to that found in PB.  
This differential regulation of receptor expression cannot be explained by different 
proportions of CD45R0 positive T cells as T cells in both SF and ST are predominantly 
CD45RO positive. The differential expression independently of CD45R0 expression was 
confirmed in 4 color staining experiments in which we co-labelled for CD4, CD3, CD45R0 
and CD126 or CD130 respectively. There is a wide range of expression of CD130 on ST 
CD4+ T cells is wide. It is normal to find variation when using human samples, various 
factors may help explain the wide range of CD130 expression. The fact that CD130 is already 
expressed at very different levels within the perivascular cuff and away from the perivascular 
cuff, may help explain this differences as some patients could have different proportion of 
cells away from the in and away from the cuffs. It is also a factor to take into account when 
looking at the expression of CD130 in confocal images that there is no way to investigate if 
underneath or above single cells there was also a blood vessel, perhaps making these cuff 
cells rather than non cuff cells. And finally a very important factor potentially affecting 
CD130 expression would be the different amounts of IL-10 present in the tissue of the 
different patients used in the study.  The observation that the ST CD4+ T cells express 
CD130, but only low levels of CD130 suggested that these cells may be a target for IL-6 
transsignaling. To test this, we performed an experiment treating SF, ST and PB cells from 
RA patients with IL-6 and IL-6/sIL-6R to investigate whether the cells are able or not to 
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respond to IL-6 directly, via transsignaling or whether they do not respond to IL-6 at all. As 
functional readout we measured STAT3 phosphorylation following the treatments. We saw 
that while ST CD4 T cells could not respond to IL-6 direct signaling, as expected from their 
higher expression of CD130, they did respond to IL-6 via transsignaling. This is an important 
observation, suggesting that CD4 T cells not only show a different phenotype in ST and SF, 
but that this phenotype also has a biological consequence. The use of STAT3 phosphorylation 
as a readout of IL-6 mediated signal transduction has been used extensively by others (224) . 
Since STAT3 signaling is activated by a number of different cytokines such as IL-10 and 
Type I interferons it is not a reliable readout for ex vivo assessment of Il-6 signaling, but in 
our experiments only IL-6 and its soluble receptor were present in the short term cultures. 
Previous work has shown that while some of the functions of IL-6 are mediated via direct 
signaling, (reviewed in (51)) ubiquitous expression of CD130 enables transsignaling to 
mediate many of the effects of IL-6 on a wider range of cell types. IL-6 transsignaling 
promotes the growth of diverse cells types such as hematopoietic progenitors (225) and 
synovial fibroblasts (226). It also triggers osteoclast differentiation in vitro (180,215,227) and 
neuronal survival and differentiation (228,229). IL-6 transsignaling has also been implicated 
in the switch from innate to acquired immune responses, crucial for an efficient inflammatory 
response, its termination and the restoration of tissue homeostasis (reviewed in (58)). 
In RA IL-6 has been proposed to play an important role, the first evidence for this is the high 
level of IL-6 found in SF and serum of RA patients (230,231). IL-6 causes some of the local 
and systemic signs and symptoms of RA such as fever, autoantibody production and joint 
inflammation (177,181). In addition, IL-6-/- mice are protected from antibody induced 
arthritis and the addition of IL-6 is not sufficient to restore disease, however when mice are 
injected with Hyper-IL-6 they do show signs and symptoms of arthritis as well as an 
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increased recruitment of CCR2+ mononuclear leukocytes, this strongly suggests that of 
antibody induced arthritis depend on IL-6 transsignaling rather than direct signaling (reviewed 
in (218)). Transsignaling has also been proposed to play a role human RA. Elevated levels of 
sIL-6R have been demonstrated in serum and SF of RA and Juvenile arthritis (91,215,216). In 
addition, the levels of sIL-6 and IL-6 have been correlated with the degree joint destruction. 
Furthermore, RA SF containing sIL-6R and IL-6 promotes osteoclast formation in vitro (215). 
So it is clear that many of the effects of IL-6 in RA are mediated by transsignaling. There is a 
natural occurring antagonist of transsignaling, the soluble form of CD130 or sgp130. sgp130 
can bind to sIL-6R/IL-6 complexes and prevent transsignaling. In RA the levels of sgp130 are 
not elevated (232). This may suggest the need for sgp130 regulation of transsignaling in RA, 
indicating a good therapeutic approach (reviewed in (218)).  
As I mention earlier a very distinctive characteristic of T cells in RA is their ability to escape 
apoptosis and remain alive in the joint for a long period of time in the joint environment. IL-6 
is a survival signal for lymphocytes but in the synovial tissue T cells are chronically exposed 
to this cytokine and they seem to become refractory to its effects due to their low expression 
of CD126. High expression of CD130, however, described on CD4 T cells in the rheumatoid 
ST may allow IL-6, when completed with sIL-6R, to act as a survival signal via 
transsignaling.  
Chronic exposure to a cytokine can lead to the down regulation of receptor expression, 
rendering the target cell refractory to this cytokine. However, our data supports that in the 
inflamed synovium, with its high level of IL-6, the expression of CD130 is maintained, even 
though CD126 expression is down regulated. Intriguingly, we observed that CD130 
expression in T cells infiltrating the ST is not distributed homogenously throughout the 
inflamed tissue. We found higher levels of CD130 expression in the T cells in the perivascular 
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infiltrates. There many possible reasons for such a distribution. The higher level of CD130 in 
this microenvironment may de due to selective migration of a subset of T cells to this site, 
alternatively it may also be reflecting local induction of CD130 gene expression. It may also 
reflect differentiation of a specific T cell subset, we showed that the synovial tissue T cells do 
not become refractory to IL-6 but can respond to sIL-6R/IL-6 complexes binding to CD130. 
The next important step is to identify factors that regulate the expression of the components of 
the IL-6R in the different compartments of the rheumatoid joint. 
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Chapter 4 
4. Mechanism of regulation of CD130 expression on T cells 
in the synovium. 
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4.1 Introduction 
In the previous chapter we have shown that the expression of CD130 is maintained high in T 
cells in the rheumatoid joint that are chronically exposed to IL-6. These cells have also been 
shown to respond to IL-6 via transignaling.  
The immune system uses cytokines for a large proportion of cell to cell communication. 
Cytokines bind to receptors found on the surface of cells and they stimulate signaling 
pathways that ultimately lead to the increase or decrease of gene transcription. The production 
of cytokines can be triggered by several stimuli such as complement, immune complexes, 
bacterial and viral components, acute phase proteins and other cytokines themselves among 
others (reviewed in (233)).  Many cytokines have been identified in the SF and synovial tissue 
of RA patients, as well as in animal models of RA (234-236). In addition, T cells from the RA 
joint share similarities with T cells that have been activated in vitro using a cytokine cocktail 
including: IL-2, IL-6 and TNF-α, highlighting the importance of cytokines in the 
pathophysiology of RA (115). In established RA, there are several key events contributing to 
the disease, the high presence of inflammatory cells in the joint, angiogenesis that provides 
oxygen and nutrition to the enlarged synovium and bone and cartilage destruction. Cytokines 
play an active role in all of these processes (reviewed in (155)). Not only do cytokines 
mediate some of the local effects seem in RA, they are also involved for systemic symptoms 
such as the production of acute phase proteins triggered by IL-6 or the cachexia triggered by  
TNF (155). We have observed high expression of CD130 on CD4 T cells clustering around 
the perivascular cuffs in ST. We wanted to study possible inducers of CD130 expression in 
the joint so we picked a panel of cytokines including: IFN-γ, IL-1α, IL-6, IL-10, IL-12, IL-15, 
IL-17, IL-23, MIP-1α, RANTES, SDF-1, TNF-α and TGF-β. We selected this panel of 
cytokines on the basis that they have all been detected in the rheumatoid joint and are known 
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regulators of T cell function or differentiation. For practical reasons we were not able to 
extend these experiments to all cytokines present in the joint. We investigated if any of these 
cytokines had an effect in CD130 expression on CD4 T cells in vitro.  
IL-1α and β have been known for some time to enhance T cells activation  and 
(237)proliferation. It is expressed at high levels in many inflammatory conditions.  IL-6 has 
been shown lead to internalization of both CD130 and CD126, the changes in IL-6 receptor 
protein expression on the cell membranes induced by IL-6 therefore could be considered as a 
positive control for the experiments(64).  IL-10 is typically an anti-inflammatory cytokine that 
prevents antigen presentation to T cells. It does, however also have direct effects on T cells 
(238). IL-10 has been detected in the RA joint by and its overproduction is linked with RA 
joint destruction (239). The main growth factor for T cells in the synovium is thought to be 
IL-15 (112). In the synovium IL-15 is produced by macrophages, endothelial cells and 
fibroblasts (240). IL-15 acts as a chemotactic factor for CD45RO positive T cells. It also 
triggers the secretion of proinflammatory cytokines: IL-6, TNF-α and IL-1 by macrophages 
(241).  
TNF-α  has been identified in most synovial biopsies of RA, its inhibition in RA mice models 
results in suppression of arthritis, its overexpression induces spontaneous arthritis (200). 
TNF-α induces the activation of leukocytes, endothelial cells and synovial fibroblasts. TNF-α 
is also a synovial fibroblast survival factor and promotes angiogenesis (reviewed in (155)). As 
a part of a cytokine cocktail it is able to activate T cells proliferation in the absence of cognate 
interaction with MHC bound antigenic peptides(113).   
SDF1 or CXCL12 has previously been shown by our group to contribute to accumulation of T 
cells in the rheumatoid synovium (242). MIP1-α (CCL3) and  RANTES (CCL5) are major 
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regulators of T cell migration (243). TGF-b, IL-23 and IL-12 were include in this study 
because they are important regulators of T cell subset differentiation and plasticity (244).   
The differential expression of CD130 by T cells in different compartments of the rheumatoid 
joint may also be explained by selective migration or induction during transmigration through 
the endothelium. T cells infiltrating the rheumatoid joint are recruited from the circulation. In 
order to infiltrate the synovium T cells must transmigrate through the endothelium. It was 
been described in the literature that in a HUVEC model of endothelial transmigration 
activated CD4 positive cells are able to acquired endothelial cell markers including: CD31, 
CD49d, CD61, CD54 and CD62E (245). We have described the differential expression of 
CD126 and CD130 on CD4 positive T cells in the rheumatoid synovium in the previous 
chapter. In this chapter we wanted to investigate the factors present in the SF and ST that 
contribute to the differential expression of CD126 and CD130. In addition we wanted to 
investigate if CD130 high expression in the RA ST was locally induced or there was a 
possibility that endothelial transmigration has an effect on the expression of CD130 on CD4 
positive T cells. 
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4.2 RESULTS 
4.2.1 IL-6 present in SF is responsible for the low expression of CD126 and CD130 on 
CD4 positive T cells from RA SF.  
So far we have observed a different IL-6R expression phenotype on CD4 T cells from SF and 
ST. We have also observed that differential expression of CD126 and CD130 influences CD4 
T cells response to IL-6 and IL-6/sIL6R. At this point we decided to investigate the cause of 
CD126 and CD130 low expression in SF CD4 T cells. An obvious candidate to be tested was 
IL-6, as  IL-6 can be internalised together with its receptor and can therefore down regulate its 
surface expression if present at high enough level (reviewed in (218). Therefore,  to test 
whether IL-6 in SF is responsible for the low expression of CD126 and CD130 on CD4 T 
cells, we isolated PBMCs from PB from healthy donors by density ficoll gradient 
centrifugation and then sorted CD4 positive T cells using the MoFlow cell sorter. As shown in 
figure 17, We treated CD4 T cells with SF in the presence and absence of an IL-6R blocking 
antibody and with IL-6 as a positive control and medium as a negative control for 1 hour. 
Then we assessed the   expression of CD126 and  CD130 on the treated cells by flow 
cytometry. An example of raw data in shown in figure 19. We observed that SF was able to 
downregulate CD126 and CD130 at the same level as IL-6. When anti-IL6R antibody was 
added to the SF before incubation CD126 and CD130 expression was  only partially 
downregulated compared to IL-6 or SF treatments (figure 20). 
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Figure 19. Expression of CD126 and CD130 on CD4 T cells treated with IL-6, SF and SF 
combined with an anti-IL-6R blocking antibody. On the left, the histogram shows the 
expression of CD126 and on the right the expression of CD130 following treatment with IL-6 
(10ng/ml for 30 minutes at 37ºC), SF treatment (30 minutes at RT) and SF plus anti-IL-6R antibody; 
anti-IL-6R antbody added at 1 µg/ml for 30 minutes incubated on ice and then SF added and further 
incubated 30 minutes at 37ºC. The black curve represents CD126 and CD130 on the left and 
right respectively and the red curve represents the irrelevant control. 
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* p value = 0.0167 
** p value = 0.0041 
 Figure 20. CD126 and CD130 expression on CD4 positive T cells following SF treatment 
and SF plus anti-IL-6R blocking antibody. Graph 17A shows the expression of CD126 on 
freshly isolated CD4 positive T cells following IL-6 treatment (10ng/ml for 30 minutes at 37ºC), SF 
treatment (30 minutes at RT) and SF plus anti-IL-6R antibody anti-IL-6R antobody added at 1 µg/ml 
for 30 minutes incubated on ice and then SF added and further incubated 30 minutes at 37ºC..Graph 17 
B shows the expression of CD130 on CD4 positive cells after IL-6, SF and SF plus anti-IL-6R 
treatment (same incubation conditions as 17A). P values were calculated using a Mann Whitney test 
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4.2.2 IL-10 may contribute to the high level of expression of CD130 demonstrated on 
CD4 positive T cells in ST.  
CD4 positive T cells in ST express high levels of CD130. We wanted to investigate the 
mechanism causing CD130 upregulation or maintenance of CD130 expression. For this 
purpose we obtained PBMCs from healthy donors by ficoll gradient centrifugation, and sorted 
CD4 positive T cells using a MoFlow cell sorter. Sorted CD4 T cells were treated with a panel 
of cytokines for 6 hours. Following treatment, the expression of CD130 was measured by 
flow cytometry and CD130 mRNA levels measured by RT-PCR. RNA was extracted from 
cytokine-treated cells. RNA was then reverse transcribed to obtain cDNA and cDNA was 
used to determine the level of CD130 mRNA by RT-PCR. Cytokine treated CD4 T cells were 
used to assess CD130 protein levels by flow cytometry. We found that IL-10 treated CD4 
positive cells have higher levels of CD130 mRNA (fig 21). We also found a concentration 
dependent upregulation of CD130 at the protein level on CD4 positive T cells treated with IL-
10 (fig 22). 
 
 
 
 
 
 
 
 
 
 
94 
 
Me
d IL6 IL2
3
RA
NT
ES
MI
P1
α
IN
Fγ
TN
Fα IL1
0
MC
P
IL1
7
IL1
5
TG
Fβ IL1
α
IL1
2
SD
F
0
2
4
6
8
10
12
14
tit
y
Cytokine treatments
m
R
N
A
 R
el
at
iv
e 
Q
ua
nt
ity
m
R
N
A
 R
el
at
iv
e 
Q
ua
n
 
 
 
 
 
 
n=1 
Figure 21: Relative quantity of CD130 mRNA in cytokine-treated CD4 T cells. This 
graph shows the relative amount of CD130 mRNA present in CD4 positive T cells following 
6 hour treatment at 37ºC with the following cytokines : IL-6, IL-23, RANTES, Mip1α, INFγ, 
TNFα, IL-10, MCP, IL-17, IL-15, TGFβ, IL-1α, IL-12 and SDF, all cytokines were used at a 
concentreation of 10ng/ml, except SDF which was used at 40ng/ml.  
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 Figure 22 . Expression of CD130 on CD4 T cells treated with IL-10. The histograms show 
the expression of CD130 on CD4 T cells that were treated with IL-10 at 1, 10 and 100 n/ml 
for 6 hours. 
  
Medium 
IL-10, 1ng/ml 
IL-10, 
10ng/ml 
IL-10,100ng/ml 
Irrelevant 
CD130 
96 
 
Control IL-6  1 10 100ng/ml
0
25
50
75
100
125
150
175
      IL-10
*
C
D
13
0 
%
 c
on
tr
ol
 
* p value = 0.0165 
n=3 
SD error bars 
Figure 23. Protein expression of CD130 induced by IL-10. Figure 23 shows the CD130 
protein expression on CD4 positive T cells following treatment with IL-10 at 1, 10 and 100 
ng/ml for 6 hours at 37ºC.  
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4.2.3 High levels of CD130 mRNA have been found in CD4 T cells in RA ST. 
We described earlier that CD4 positive T cells in the perivascular areas of RA ST show high 
levels of expression of CD130 at the protein level. We wanted to determine if this was 
reflected in the CD130 mRNA expression. For this purpose, we obtained PBMCs by ficoll 
gradient centrifugation and STMCs by tissue mechanical degradation followed by ficoll 
gradient centrifugation. Then CD4 positive T cells were sorted by flow cytometry. Sorted 
cells were used for RNA extraction followed by reverse transcription to obtain cDNA. cDNA 
was used for RT-PCR to determine the relative quantity of CD130 mRNA present in CD4 
positive cells from ST compared to PB. The level of CD130 mRNA was higher in ST CD4 T 
cells compared to PB (figure 24). 
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Figure 24. CD130 mRNA levels on CD4 positive T cells in RA ST. This graph shows the 
relative quantity of CD130 mRNA present in CD45RO positive CD4 T cells obtained from PB and ST 
paired samples of RA patients. 
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4.2.4 In vitro endothelial transmigration does not have an effect on CD130 expression on 
CD4 positive cells. 
CD130 is expressed at high levels on CD4 positive T cells in the perivascular areas of ST. We 
wanted to investigate if endothelial transmigration was responsible for this. To test this we 
used a model established in the Department of Physiology of the University of Birmingham. 
 We grew monolayers of HUVEC cells and sorted CD4/ CD45R0 double positive cells from 
PB of healthy donors. We stimulated HUVEC cells with TNF-α and IFN-γ (100u/ml and 
10ng/ml respectively) for 24 hours and rinsed off. HUVEC and freshly isolated T cells were 
co-cultured with CD4 T cells on top of the HUVEC cells for 24h hours in the presence and 
absence of IL-10 at 10ng/ml. After incubation we collected the CD4 T cells that had crossed 
the HUVEC monolayer and the cells that did not cross the HUVEC monolayer and remained 
on top of the monolayer. Finally we looked at the expression of CD130 of transmigrated and 
non-transmigrated CD4 T cells by flow cytometry. Examples of raw data are shown in figure 
25. The expression of CD130 was similar in migrated and non-migrated cells and similar to 
freshly isolated cells that were not exposed to the HUVEC cells. CD130 expression was 
slightly higher on both non transmigrated cells and on transmigrated cells in the presence of 
IL-10 (figure 26). So we conclude that transmigration through a monolayer of HUVEC does 
not change the expression of CD130 on CD4 positive T cells in vitro, making it unlikely 
transendothelial migration in vivo has an effect on CD130 expression. 
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 Figure 25. CD130 expression on CD45RO positive CD4 T cells following exposure to a 
HUVEC monolayer of cell. The histograms show the expression of CD130 on CD45RO positive 
CD4T cells from healthy donors before and after transmigration through a monolayer of HUVEC 
cells. HUVEC cells were stimulated with TNFα (100u/ml) and IFNγ (10ng/ml) for 24 hours and CD4+ 
T cells were incubated on top of the HUVEC monolayer for 24h at 37ºC.  
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Figure 26. CD130 expression on HUVEC transmigrated and non-migrated CD4 T cells 
in the presence and absence of IL-10.  This graph shows the expression of CD130 on 
CD45RO positive CD4T cells from healthy donors before and after transmigration through a 
monolayer of HUVEC cells. HUVEC cells were stimulated with TNFα (100u/ml) and IFNγ 
(10ng/ml) for 24 hours and CD4+ T cells were incubated on top of the HUVEC monolayer for 
24h at 37ºC.  
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4.2.5 Localization of IL-10 and IL-6 expression within the rheumatoid joint. 
The data shown above suggest that both IL-6 and IL-10 may have a role in the regulation of 
the expression of both chains of the IL-6 receptor in patients with rheumatoid arthritis. We 
therefore decided to study their localization in ST. While the localization of IL-10 in the 
perivascular infiltrate has been described before, we wanted to be able to investigate its 
localization in the tissue samples in which we had investigated the distribution of IL-6R 
receptor components. We stained frozen sections of synovial tissue with anti-IL-6 and anti-
IL10 to asses the presence and distribution of the two cytokines. The images shown in figure 
27 clearly demonstrate the presence of IL-6 and IL-10 in the joint. IL-6 was localized mainly 
in not heavily infiltrated areas while IL-10 was found mostly in the perivascular cuff areas 
with heavy presence of inflammatory infiltrate. 
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Figure 27. Confocal images of IL-6 and IL-10 in ST sections.  
Figure 22  is a confocal picture of a synovial tissue sections, on the left: stained with anti-IL-6, anti-
CD3 and a nuclear counterstain DAPI (grey). On the right a confocal image of a synovial tissue 
stained with anti-IL-10 and a nuclear counterstain DAPI. The arrows in the picture point the 
perivascular cuffs. 
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4.3 DISCUSSION  
In the previous chapter we have described the different IL-6R phenotypes found in SF and ST 
CD4 T cells and we showed a biological function derived from these different phenotypes. In 
the work shown in this chapter we further investigated the potential mechanisms that may 
explain these two different phenotypes in SF and ST CD4 T cells. From the literature we 
knew that IL-6 is present in very high levels in the SF of RA patients (246), and that that IL-6 
can downregulate the expression of both chains of its receptor (64). We decided that IL-6 
present in SF would be a good candidate to explain CD126 and CD130 downregulation in SF. 
We treated fresh CD4 T cells with SF and SF combined with an anti-IL6R blocking antibody 
and observed that indeed SF downregulates CD126 and CD130. This downregulation was 
prevented by an anti-IL6R blocking antibody. We therefore suggest that the IL-6 present in 
SF of RA patients may cause the low expression of the IL-6R chains on CD4 T cells. 
However, IL-6 is also expressed in the synovial tissue, raising the question why CD130 is not 
downregulated on T cells in the tissue. Therefore we looked for mechanisms that could 
explain why CD130 remains highly expressed in ST CD4 T cells. We did not have a very 
obvious candidate for this so we used a panel of cytokines, present in the RA SF and 
representative of all cytokine families, to treat CD4 T cells and analyze their effect on 
expression of CD130 on the protein and gene transcription level. To our surprise we found 
that IL-10 treated CD4 T cells showed high levels of CD130 mRNA and also showed an 
upregulation of CD130 at the protein level. IL-10 is a homodimeric cytokine produced by a 
wide variety of cells, the major sources of IL-10 include: Th2, Th1, a type of Treg known as 
Tr1, CD8T cells, monocytes, macrophages, some subsets of DCs, B cells, some granulocytes 
and some non-immune cells such as epithelial cells or tumor cells (80). New data from our 
laboratory, however, suggests that most of the IL-10 in the RA synovium is produced by 
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macrophages. IL-10 is traditionally seen as an anti-inflammatory cytokine, it inhibits the 
activation of monocytes, macrophages and dendritic cells which in turn results in a reduced 
production of proinflammatory molecules such as cytokines and chemokines necessary for 
CD4 T cell activation and stimulation. In contrast, IL-10 has some proinflammatory or 
stimulatory effects on other cell types. It induces recruitment of CD8 T cells and stimulates 
their proliferation and cytotoxic activities. It also stimulates the proliferation of B cells, 
enhancing their antibody production (86). The presence of IL-10 in the rheumatoid joint has 
been demonstrated in by immunohistochemistry and PCR(182). It has been shown to be 
produced in the rheumatoid joint by T cells and macrophages. It has been associated with a 
reduction in the release of anti-inflammatory cytokines in the joint and therefore it is thought 
to have a proinflammatory effect. However, IL10 has also been associated with an increased 
of autoantibody production by B cells, and its mRNA level has been correlated to joint 
damage. This observation is supported by the results of a two year retrospective study which 
showed that the synovial membrane mRNA level of IL-10 together with other cytokines is 
predictive of a high level of joint destruction in RA (185). Another study revealed that IL-10 
genotype associated with higher production of IL-10 was observed in patients showing higher 
rate of joint destruction (184). 
The anti-inflammatory effect and immunomodulatory action of IL-10 have been highlighted 
experimentally using animal models of human disease. IL-10 knockout mice spontaneously 
develop an inflammatory lethal condition affecting their intestine which can be reversed by 
adding IL-10 (247). Following this observation, IL-10 was administrated to treat animals with 
various animal models of colitis successfully (reviewed in (248)). IL-10 treatment was 
beneficial in various experimental models of inflammation including: experimental 
autoimmune encephalomyelitis (249), pancreatitis (250), diabetes mellitus (251), and some 
106 
 
models of arthritis (252). However, the use of IL-10 in experimental allergic encephalitis 
showed controversial results being successful in some studies and unsuccessful in others 
(253,254). Clinical trials conducted to test the use of rIL-10 as an anti-inflammatory agent in 
RA, however, did not lead to clinical improvements. In a study conducted by van Roon and 
colleagues, 10 RA patients were treated with rIL-10 without convincing therapeutic effect 
according to the ACR criteria, in addition rIL-10 treatment caused the adverse effect of 
thrombocytopenia and the upregulation of the Fc gamma RI and Fc gamma RIIa on 
circulating monocytes/macrophages and an increase in TNF-α production. The upregulation 
of Fc gamma R may contribute to immune complexes formation and may therefore counteract 
the potential anti-inflammatory effects of IL-10 (255). Similarly, the administration of rIL-10 
to sufferers of Crohn’s disease in clinical trials showed disappointing results with no clinical 
remission or symptom reduction (254). However, the use of IL-10 in clinical trials to treat 
psoriasis has been very promising showing improvement of the condition as well as reducing 
relapse (256,257). Psoriasis is a T cell mediated autoimmune disease affecting the skin. It is 
believed that specialized APC present psoriatic antigen to T cells, IL-10 has been suggested to 
interfere with APC activities and triggers a shift from Th1 like to Th2 like response (reviewed 
in (248)). Taken together, these studies do suggest that there is no straightforward clinical 
application for recombinant IL-10 in inflammatory disease, and that it’s pro and anti-
inflammatory functions are more complex than anticipated from the studies in murine models. 
 It is not understood to date whether IL-10 is expressed in the synovium as a 
counterregulatory factor, produced by the immune system in an attempt to down-modulate the 
inflammatory process or whether it is functioning as a proinflammatory agent. Whatever the 
case is, our experiments suggests that IL-10 may contribute to upregulate or maintain CD130 
expression on CD4 T cells in the ST allowing IL-6 to remain a survival and differentiation 
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signal to these cells via transsignaling. So whatever the mission of IL-10 in the synovium is, 
this cytokine may become an accomplice of IL-6 in T cells survival and RA chronic 
inflammation. 
Even though we have identified IL-10 as a candidate factor that could cause the upregulation 
or maintenance of expression of CD130, this does not provide evidence of its role in vivo. 
There are several possibilities, one is that PB T cells that express high levels of CD126 and 
CD130 infiltrate the joint and CD126 expression goes down in the presence of IL-6 but 
CD130 remains high due to the presence of counter-regulatory factors, such as IL-10 that may 
induce de novo production of CD130. This interpretation is supported by the high levels of 
CD130 mRNA in ST CD4 T cells compared to PB. Increased mRNA expression in the tissue 
T cells is compatible with our hypothesis that it is induced locally. However, CD130 
expression can also be explained by selective migration of CD130 high cells from the blood. 
Low expression mRNA expression in these cells would have indicated that it is unlikely to be 
induced locally. There is little information regarding the regulation of CD130 at the gene level 
in the literature, CD130 mRNA levels have been described to be upregulated in rat brains in 
response to LPS but not in response to rIL-1β (258) . Falus and colleges studied the effect of 
various compounds on the levels of CD130 mRNA on several human cell lines. They found 
that CD130 mRNA is downregulated in U266 and BMNH by TPA. CD130 mRNA is also 
downregulated in U937 by DB-cAMP and upregulated in U266 by dexamethasone (259).  
Another reasonable hypothesis would be that endothelial transmigration triggers CD130 
expression on CD4 T cells when they travel through the blood vessels and into the synovium. 
We tested this in vitro, by assessing the effect of endothelial transmigration on the expression 
of CD130 on CD4 T cells and found that CD130 expression is not affected in the presence 
and absence of IL-10. Obviously it is very hard to extrapolate in vitro experiments to the 
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actual situation in vivo where there are may be additional factors that are absent in-vitro. It is 
therefore possible that endothelial transmigration does influence CD130 expression in RA but 
the in vitro data suggests that that is not the case.  
We stained RA ST sections for IL-6 and IL-10 to confirm the presence of these cytokines in 
the joint and to determine the distribution of the two cytokines in the rheumatoid synovium. 
We found, in agreement with previous publications, that IL-6 and IL-10 are both present in 
the synovium. IL-6 appears to be particularly high in non infiltrated areas, but is present 
throughout the synovial tissue. In turn IL-10 is expressed mostly in perivascular cuff areas 
with high numbers of infiltrating cells. We did not investigate the source of IL-6 and IL-10 in 
the RA joint but it would be interesting to determine which cells are secreting these two 
cytokines. The presence of IL-6 in the ST explains low expression CD126 on CD4 T cells, 
However, it this case it would have been expected to see loss of CD130 expression as well. 
IL-10 may explain or at least in part the higher levels of CD130 expression on CD4 T cells in 
the perivascular areas of the ST. IL-10, probably together with other factors that may cause 
CD130 upregulation by de novo production. The long term exposure of CD4 T cells to IL-6 in 
the RA joint makes them downregulate the IL-6 receptor and they probably would become 
insensitive to IL-6 if CD130 expression was not upregulated,  caused by high levels of IL-10 
(and may be other factors) in the perivascular cuff making these cells sensitive to IL-6 via 
transsignaling. So IL-6 may be a survival factor for CD130 high expressing CD4 T cells in 
the rheumatoid joint contributing to their ability to escape apoptosis and keep contributing to 
the chronic inflammation seen in RA. 
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Chapter 5 
 
5. T cell activation status and presence of iNKT cells in 
very early rheumatoid arthritis. 
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5.1 Introduction 
In earlier work done in our research group, Raza et al described a unique and transient 
cytokine panel in very early rheumatoid arthritis patients, this are patients that have suffered 
the symptoms for no longer than three months. The panel of cytokines described by Raza et al 
included:  IL-4, IFNγ, IL-2, IL-5, IL-6, IL-13, IL-13, IL-17, IL-21, TNF-α, TGF-β and GM-
CSF. Since iNKT cells are a source of IL-4 and IL-13 we hypothesized that iNKT cells may 
be enriched in the synovium of very early RA patients and therefore in this chapter we 
investigated the presence of iNKT cells in the SF of established RA patients with more than 3 
months symptom duration compared to very early RA patients. Samples of Very Early 
arthritis were collected at the very Early RA clinic run by Dr. Karim Raza in City Hospital in 
Birmingham, where patients present with undefined synovitis. Full diagnosis of the patients 
would be then obtained overtime a shown in figure 28. In the very early RA  group it has been 
described a transient cytokine profile Raza et al  from which we conclude that T cells may 
have different roles in the different stages of the disease. Therefore their activation status 
could be different in the different stages of RA, so we investigated the activation status of T 
cells in the SF of very early RA patients compared to established RA patients. 
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Figure 28. The different outcomes of very early synovitis 
iNKT cells are a T cells subset with which have the particular characteristic to modulate the 
immune system by secreting a different range of cytokines in different situations being able to 
trigger both Th1 and Th2 responses. The role of iNKT cells in rheumatic disease has been 
extensively studied in the past few years. Reduced numbers of iNKT cells and impaired 
functionality have been reported in animal models genetically susceptible to various 
autoimmune diseases including type I diabetes, SLE and RA reviewed by (169). The 
involvement of iNKT cells in murine models of RA has been reported in several studies. 
iNKT cells appear to be necessary for the induction of mice CIA. It has been reported that 
CIA is substantially less severe in iNKT cell KO mice and mice in which iNKT cells have 
been blocked with anti-CD1d antibodies compared to WT mice (260). CIA is characterized by 
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pro-inflammatory Th1 type cytokines, OCH, an analogue of αGal-Cer, stimulated iNKT cells 
to produce Th2 cytokines. When administered to mice OCH  collagen induced arthritis was  
ameliorated (reviewed by (169) while the same effect could not be achieved in iNKT cell 
deficient mice (168) In another model of RA, antibody induced arthritis, in which arthritis is 
triggered by transfer of serum from K/BxN mice, which spontaneously develop joint 
autoimmune inflammation, to healthy mice, this leads to auto-antibody deposition in the joint 
and subsequent inflammation triggered by activation of complement and Fcgamma receptor 
pathways (reviewed by (169). Joint inflammation was  deficient in the absence of iNKT cells 
(261). Since iNKT cells seem to be a potential contributor to the development of arthritis we 
decide to study the presence of this cell type in the PB and SF in the early stages of RA 
compared to other inflammatory conditions and with later stages of RA. While there is a 
considerable body of literature on the presence of activated T cells in patients with 
rheumatoid arthritis (262-264), there has not been a systematic study of the level of T cell 
activation in the very early stages of disease. Since our previous work on cytokine expression 
has suggested a different role in the stages of RA development, we investigated the level of 
expression of activation markers in RA.   
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5.2 RESULTS 
5.2.1 T cells in very early arthritis RA SF express the activation markers CD25, CD69, 
CD71 and HLA-DR. 
We investigated patients recruited from the Birmingham Early Arthritis Clinic. These patients 
were recruited within the first 3 months of joint swelling and at 18 months depending on  
disease outcome, were classified as having RA, resolving arthritis, or chronic arthritis other 
than RA. Patients with established RA were either recruited from the early Arthritis Clinic 
after 3 months of symptoms or from other arthritis clinics in Birmingham. Cells in whole SF 
and whole blood were stained with the appropriate directly labeled antibodies for flow 
cytometry, red blood cells were lysed and cells were read in the flow cytometer to determine 
the level of expression of CD25, CD69, CD71 and HLA-DR in CD3 positive T cells from PB 
and SF samples, an example of the staining is shown in figure 29. 
All activation markers are upregulated in SF compared to blood but no significant differences 
are observed in the different patient groups. The percentage of CD25 positive T cells in PB of 
all patients is slightly lower than in healthy controls but still at comparable levels. In SF 
CD25 is lower in early arthritis patients but the difference is not statistically significant  CD69 
and CD71 are expressed at very low levels in PB of all patients and controls but significantly 
higher in SF of all patients. HLA-DR is very low in PB but higher in SF (figure 30). In 
summary, while we detected an increased number of CD69, CD71 and HLADR positive T 
cells in the SF of most patients, there was no significant difference in the expression of 
activation markers in the groups of arthritis patients investigated here.   
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Figure 29. CD25, CD69, CD71, HLA-DR expression on CD3 positive cells from PB and 
SF. Figure 23 shows the number of CD3 positive cells that are also positive for the activation markers 
CD25, CD69, CD71 and HLA-DR in PB and SF samples of RA patients.  
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* p value <0.05 ** p value = 0.0006    *** p value = 0.0041 **** p value = 0.0001  
(Kruskal-Wallis Test) 
Figure 30. Expression of T cell activation markers on PB and SF.  
The graphs show the expression of CD25 (figure 24A), CD69 (figure 24B), CD71 (figure 
24D), and HLA-DR (figure 24C) on T cells in PB and SF of very early RA patients, Very 
early synovitis (other than RA) patients, established RA patients and healthy controls.   
VEA to RA: patients with very early synovitis that become RA patients 
VEA to Other: Very early synovitis patients that develop a condition other than RA and 
patients that resolve the synovitis. 
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Figure 31. CD3 versus iNKT. 
An example of a staining of a healthy control PBMC with anti-CD3 versus anti-iNKT. On the 
left an irrelevant control for iNKT and on the right the actual staining CD3 versus iNKT gated 
on the lymphocyte population in the FS/SS 
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 * p value = 0.019 (Mann Whitney test) 
Figure 32. iNKT cells in PB and SF.  
This graph shows the percentage of iNKT cells amongst CD3 positive cells in PB and SF from Very 
early RA and non RA patients, Established RA patients and healthy controls. 50,000 events were run 
in total per sample. The absolute numbers of iNKT cells found are extremely low between 0 and 30 
cells. 
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5.2.2 The levels of iNKT cells in PB and SF of Early arthritis (RA and non RA), 
established arthritis and healthy controls.  
The percentage of iNKT cells was quantified in the PB and SF of early arthritis and 
established RA patients as well as healthy controls by flow cytometry. PBMCs and SFMCs 
were obtained by ficoll gradient centrifugation.  Cells were stained with anti-CD3, anti-iNKT 
and anti-CD25/CD69/CD71/HLA-DR and the percentage of positive iNKT cells was obtained 
gating on the CD3 positive lymphocyte population. 50,000 events were run per sample. The 
level of iNKT cells in the PB of early arthritis and established RA does not significantly differ 
from the level in the PB of healthy controls.  The percentage of iNKT cells is lower in SF 
compared to paired PB samples. All groups of patients show reduced numbers of iNKT cells 
in the SF but very early RA patients show the lowest number and it is significantly lower than 
e number of iNKT cells in the SF of established RA patients (Mann-Whitney test, p value = 
.019) (figure 32) 
th
0
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 5.3 DISCUSSION  
T cells are thought to contribute to disease pathology in RA; they are present infiltrating the 
synovial tissue of RA patients in RA SF. Their role and interaction with other cells in RA has 
been studied extensively. While the pattern of activation markers expressed by T cells in 
established RA has been subjected to considerable research, the activation status of T cells in 
PB and SF of patients with very early stages of RA has not been investigated so far. We found 
that the frequency of CD69 and HLA-DR positive cells are upregulated in SF of all patients. 
The frequency of CD25 expressing cells is slightly but not significantly increased in both 
blood and SF, being slightly lower in the SF of early RA patients. The frequency of CD71 
positive cells is slightly higher in SF compared to blood in all patients but the differences are 
both significant. The marked upregulation of CD69 and HLA-DR suggests that T cells not 
only are present in the rheumatoid synovium but they are also activated and therefore most 
likely contributing to the chronic inflammatory process seen in RA. CD69 is an activation 
marker which gets upreglated very early upon activation, even though we showed high 
frequency of CD69 expressing T cells in the SF we cannot know is whether these cells 
become activated once in the joint or if they were previously activated outside the joint and 
are then selectively recruited. Previous work shows that Influenza specific T cells can be 
detected in the joint of RA patients after vaccination, suggesting that a proportion of the T 
cells found in the synovium are activated outside the joint (reviewed in (265)). It is 
noteworthy as well the fact that T cell activation could happen independently of antigen 
encounter in RA, it was shown that synovial T cells resemble cells activated by a cocktail of 
cytokines without TCR engagement (Brennan et al. 31-41) The positive results from the 
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abatacept trials indicate that T cell activation is important even in late stage  disease, as 
interfering with T cell activation proves beneficial for RA patients  (reviewed in (212)). 
We can conclude from these experiments that there is no difference in the activation status of 
SF T cells in very early and established RA. In both cases SF T cells show high expression of 
activation markers CD69 and HLA-DR. We can also conclude that our activation markers 
(CD25, CD69, CD71 and HLA-DR) have no value as prognostic markers as they show no 
differences in the different patient groups and stages of RA. As I mention in the results 
chapter, iNKT cells are present in PB of early RA, early arthritis and established RA at a 
normal level that compares very well with our healthy control group. These findings are in 
disagreement with previous publications that claimed reduced frequency of iNKT cells in the 
PB of RA patients as well as other rheumatic patients such as SLE or systemic sclerosis 
patients (266). We also compared the levels of iNKT cells in the SF of the different patient 
groups and interestingly, we found that at a very early stage of RA (less than three months 
since the first symptoms began) the numbers of iNKT cells in SF are significantly reduced 
compared to established RA patients and early arthritis patients that develop a disease other 
than RA. However, the total number of iNKT cells was very small, making it very difficult to 
identify a biological significance.  And due to small numbers of cells we could not sort iNKT 
cells or asses their activation status. 
One possibility is that iNKT cells have an anti-inflammatory effect trying to dampen down 
inflammation at a very early stage of RA by promoting Th2 responses and that there are not 
sufficient numbers of iNKT cells to achieve clearance of inflammation, especially at the very 
early stage of RA. Alternatively it is possible that iNKT cells are pro-inflammatory in the 
context of RA and at very early stages they promote Th1 responses contributing to the 
development of RA and their lower numbers at this stage could be explained as iNKT cells 
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undergo apoptosis following cytokine secretion (reviewed in (17)). iNKT cells could be 
recruited to the joint in very early RA, They could secrete pro-inflammatory cytokines and 
undergo apoptosis, then they would be lost for a period of time until more iNKT cells are 
generated and recruited to the joint. An additional explanation could be that iNKT are actually 
Clearly we have disproved the hypothesis that enrichment of iNKT cells in the synovium 
leads to the upregulation of IL-4 and IL-13 in very early RA. 
present in the RA synovium in greater numbers but they have downregulated their TCR and 
we could not identify them.  
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Chapter 6. 
DISCUSSION  
Cells chronically exposed to cytokines will respond by the initiation of counterregulatory 
mechanisms to limit the extent of the signal received. Thus the target cells are often rendered 
refractory to that cytokine. These mechanisms include downregulation of receptor expression, 
downregulation of signalling molecules as well as upregulation of molecules that are having 
an inhibitory effect on cytokine signal transduction such as SOCS and PIAS. 
However, our data suggests that in the inflamed synovium, with its high level of IL-6, the 
responsiveness to IL-6 is maintained by transsignaling. The success of IL-6 targeting therapy 
underlines the importance of IL-6 in RA pathology. While it affects many cell types, for 
example B cells and fibroblasts, its role in the biology of T cell responses is particularly 
intriguing. It is one of the factors that regulate differentiation of T cells into Th-17 or Treg 
cells and therefore can affect the outcome of an inflammatory response. Furthermore it is 
known to be a T cell survival factor. To study the potential responsiveness of T cells in the 
inflamed rheumatoid joint, we investigated the differential expression of the two components 
of the IL-6 receptor CD126 and CD130. We have shown that expression of CD130 is 
maintained in T cells in the synovial tissue, even though CD126 expression is downregulated. 
In agreement with this observation, although synovial tissue T cells are refractory to IL-6 on 
its own, they will respond to soluble IL-6/IL-6R complexes. Induction of CD130 expression 
by IL-10 may be an explanation for this observation.  
IL-6 is an important part of the network of proinflammatory cytokines found at sites of acute 
and chronic inflammation. (267), TNF-α  (268), (reviewed by (48). Specific cell types 
respond differently to cytokine stimulation in regards of IL-6 production. For example, bone 
marrow cells produce little IL-6 when stimulated by IL-1 but high levels when stimulated by 
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IL-3, on the other hand fibroblasts stimulated with IL-3 produce low amounts of IL-6 but 
much higher amounts when stimulated with IL-1 (reviewed by (48). The IL-6 receptor as a 
complete CD126/CD130 complex is expressed by a limited number of cell types including 
hepatocytes and lymphocytes. CD130 can also be expressed independently of CD126 and is 
found in almost all cell types. Transsignaling is important as it allows IL-6 to influence cells 
that are not expressing the IL-6 receptor. As CD130 is expressed ubiquitously, IL-6 has the 
potential to signal to many cell types. The response of a cell to IL-6 signalling can be 
regulated through a number of pathways described in the literature; STAT3 activation 
enhances the expression of various genes, amongst others the genes coding for SOCS1 and 
SOCS3. SOCS3 inhibits the JAK-STAT pathway and therefore acts as an intracellular 
negative feedback for IL-6 signaling. Furthermore, IL-6 signalling can be limited by the 
downregulation of the IL-6 receptor caused by internalization of the receptor following IL-6 
binding. These negative feedback mechanisms limit the amount of IL-6 signal that a cell can 
receive. (51). IL-6 has several pro-inflammatory functions that affect both local and systemic 
inflammation. It contributes to local inflammatory processes by activating endothelial cell 
production of IL-8 and monocyte chemoattractant proteins, and also by triggering the 
expression of adhesion molecules which in turn facilitate the recruitment of leukocytes to the 
site of inflammation. IL-6 also stimulates the proliferation of synoviocytes and the activation 
of osteoclasts. Furthermore, it contributes to systemic inflammation by its involvement in the 
acute phase response. It triggers the production of acute phase proteins such as CRP by 
hepatocytes. Acute phase proteins cause complement activation which leads to induction of 
proinflammatory cytokines and neutrophil chemotaxis. IL-6 is also associated with the 
induction of fever and the secretion of hepcidin, an iron regulatory protein. Important effects 
of IL-6 on immune cells include the differentiation and stimulation of B cells to produce 
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antibodies, T cell activation and differentiation and macrophage differentiation (reviewed by 
(269). In addition, IL-6 favors the differentiation of CD4 T cells into proinflammatory Th17 
cells. CD4 T cells have the potential to differentiate into an ever increasing number of T cell 
subsets. Among these are Treg and Th17 cells. Tregs are associated with self tolerance 
(reviewed by(9)) but Th17 cells are considered as proinflammatory cells and have been 
proposed to play an important role in RA (reviewed by (7)). In mice, TGF-β is required for 
the differentiation to both Treg and Th17 but IL-6 is thought to favor the differentiation of T 
cells toward Th17 (270). 
There is clear evidence derived from animal models and patients that IL-6 is a key factor in 
the pathology of RA. Elevated levels of IL-6 and sIL-6R have been demonstrated in both 
serum and SF of RA patients (217). Even though IL-6 has been found also in OA the levels 
are not as high as in RA (246). In RA synovial fibroblast show an increased production of IL-
6 (271). IL-6 levels have been reported to correlate well with markers of disease activity such 
as RF or CRP (272) and clinical manifestations of the disease such as morning stiffness or 
number of inflamed joints (173). Intriguingly, there is even a correlation of severity of 
symptoms that follows the circadian rhythm of IL-6 production. IL-6 production peaks in the 
morning when RA symptoms, particularly joint stiffness are particularly severe. Conversely, 
IL-6 levels are lower in the afternoon and evening where discomfort for RA patients is less 
severe (reviewed in (273)).  Treatment with disease modifying anti-rheumatic drugs is 
associated with a decrease in IL-6 which in turn correlates with improvement in symptoms 
(274). In animal models it has been observed that reduced levels of IL-6 are protective against 
arthritis while excess IL-6 signaling is linked to arthritic disease development (reviewed by 
(269). IL-6 deficient mice are resistant to the development of CIA (275) while mice with a 
CD130 mutation that enhances IL-6 signaling results in spontaneous development of an 
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inflammatory disease of the joints (276). In addition to this, IL-6 deficient animals resistant to 
CIA do only develop arthritis when injected with IL-6 when it is given as a soluble complex 
with, sIL-6R (181). This observation strongly suggests an important role for IL-6 
transsignaling in the joint. Taken together, a clear importance for IL-6 in arthritis has been 
demonstrated in a range of human and animal studies. IL-6 is also known as an important 
regulator of lymphocyte differentiation and survival.  The relative importance of direct and 
transsignaling is largely regulated by the relative expression of the two components of the IL-
6 receptor and by the availability of IL-6 and the soluble receptor. sIL-6R has been 
demonstrated to be produced by naïve and memory CD4 T following TCR engagement, 
activated CD4 T cells shed the IL-6R of their cell membrane(277). The production of sIL-6R 
by autoreactive CD4T cells may be an important source of sIL-6R in autoimmune disease 
making CD126 lacking cells, such as synoviocytes, a target for IL-6 transsignaling (62). 
Secretion of the sIL-6R has also been reported in neutrophils and macrophages(reviewed 
in(58)    
In this study, we investigated the expression of CD126 and CD130 on CD4 positive T cells 
from the SF and ST of RA patients. We have found three different phenotypes in the three 
different compartments studied. In PB of our patients, CD126 and CD130 are both expressed 
at fairly high levels. In the SF both CD126 and CD130 have almost disappeared from the cell 
surface of CD4 positive T cells and interestingly in the ST CD4 T cells express very low 
levels of CD126 but higher levels of CD130. This is a very interesting finding as high 
expression of CD130 makes ST CD4 T cells a potential target for IL-6 transsignaling. The 
same pattern of CD126/CD130 expression was reproduced when we compared CD45RO 
positive CD4 positive T cells from PB, SF and ST. We confirmed the high expression of 
CD130 on CD4 positive T cells in the ST using immunohistochemical staining and confocal 
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microscopy, in addition we observed that high expression of CD130 was particularly found on 
CD4 T cells clustering together around the perivascular cuffs and that CD130 expression on 
CD4 positive T cells becomes lower as CD4 T cells move away from the perivascular cuff 
areas, until they reach the SF where the expression of CD130 is virtually lost. So we observed 
a phenotype on CD4T cells in ST, particularly in the perivascular cuff areas that suggests that 
these cells do not become insensitive from chronic exposure to IL-6, but maintain sensitivity 
to IL-6 transignalling. In addition, the observation that CD130 expression is lower in cells 
dispersed throughout the tissue when compared to those in the perivascular cuff, suggests that 
a factor present in the cuff upregulates or maintains the expression of CD130 on CD4 T cells. 
Alternatively, high expression of CD130 may keep the cells clustering together in the cuff and 
when the expression of CD130 drops cells are able to move away from the cuff. Oberg et al 
investigated the expression of CD126 and CD130 on PBMCs from healthy individuals. They 
found high expression of both CD126 and CD130 on CD14 positive monocytes, lack of 
CD126 and CD130 expression on CD56 positive NK cells, CD19 positive B cells expressed 
no CD130 and CD126 only to a certain extent, CD8 positive T cells were shown to express 
high CD126 and varying levels of CD130. CD4 positive T cells expressed high levels of both 
CD126 and CD130, in agreement with our data, although they also found a small proportion 
of CD4 T cells with high CD126 and low CD130  expression (278). Interestingly, this group 
also looked at the expression of CD126 and CD130 in tonsil and spleen (of mice) and they 
found that CD126 and CD130 were slightly higher in tonsil compared to PB but lower in 
spleen on CD4 T cells (253). Betz and colleagues investigated the expression of CD126 and 
CD130 on T cells in their different developmental stages. They showed that thymocytes 
express CD130 all throughout thymic development but only acquired CD126 expression 
when they reached either the CD8 or CD4 single positive stage. In peripheral blood, this 
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group found that T cells express both CD126 and CD130, which does agree with our own 
results. They also demonstrated that both CD126 and CD130 are downregulated upon TCR 
engagement and that CD126 low, CD130 low T cells in the PB show markers typically found 
on memory T cells (279).  
It has been reported that the loss of IL-6R expression on CD4T cells during inflammation 
gives transsignaling a role in the maintenance of Th17 cells (280). In addition STAT3 
activation via transsignaling in various models of arthritis contributes to neutrophil and T cell 
retention, including IL-17A producing T cells in the synovium (277). Our own work is in 
agreement with the low expression of IL-6R, and we showed functional contribution of IL-6R 
expression on T cells of RA patients. Gathering these studies together we could postulate that 
in RA maintenance of CD130 expression, brought about by IL-10, which allows for IL-6 
transsignaling could be an important mechanism for maintenance, retention and viability of 
Th17 cells, clear contributors to autoimmunity and inflammation. In contrast Tregs have been 
reported to express low normal levels of CD126 and low levels of CD130(278). If we looked 
at Tregs in the synovium they would have downmodulated CD126 due to the high level of IL-
6 available and they would have no potential power to respond to IL-6 via transsignaling so 
we would be left with Tregs that could not benefit from IL-6 signalling, the possible 
regulatory effects of Tregs in the joint are limited while Th17 cells are favored by CD130 
expression and transignalling. 
Having established the three different CD126/CD130 phenotypes found on CD4 T cells from 
PB, SF and ST of RA patients, we then addressed the question whether there is a biological 
consequence derived from the differential expression of CD126 and CD130 in the different 
compartments of RA patients. We know that IL-6 can signal directly by binding to CD126 
and then associating with the signal transducer CD130 or via transsignaling when IL-6/sIL-6R 
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complexes binding to CD130. We demonstrated that CD4 T cells from blood are able to 
respond to both IL-6 and IL-6/sIL-6R complex. This capacity of PB CD4 T cells to respond to 
IL-6 directly and via transsignaling is likely to be mediated by their high expression of 
CD126 and CD130. On the other hand, SF CD4 T cells, lacking expression of CD126 and 
CD130, did not respond to either IL-6 or IL-6/sIL-6R complex. In contrast, CD4 T cells from 
ST with their low levels of CD126 and high levels of CD130 cannot be stimulated by IL-6 
alone. However, they are able to respond to IL-6/sIL-6R complex treatment. In conclusion, 
the responsiveness to either IL-6 or IL-6/sIL-6R complexes is in agreement with the receptor 
expression and suggests that the differential receptor expression has a biological significance. 
In agreement with our finding that IL-6 signals to CD4+ T cells from ST  via transsignaling , 
Oberg et al reported that Tregs  with low CD130 expression, lacked response to IL-6/sIL-6R 
complex when compared to T cell populations with higher levels of CD130 expression 
(reviewed in (269).  
Data derived from the experiments by Teague and colleagues suggests that IL-6 can rescue 
mouse T cells from apoptosis in vitro by inducing or maintaining high Bcl-2 expression levels 
(50). Our own data suggests that CD4 T cells in the ST can recognize IL-6 via transsignaling 
and since IL-6 has the potential ability to rescue T cells from apoptosis. We suggest that IL-6 
transsignaling provides a potential survival mechanism of T cells in the rheumatoid joint 
which in turn contributes to the ongoing inflammation and chronicity of the disease. 
The role of transsignaling in the joint has previously been demonstrated by Jones and 
coworkers (181). They demonstrated high levels of sIL-6R in the SF of RA patients when 
compared to OA. This elevation was correlated positively with IL-6 levels. Although the 
major source of sIL-6R is membrane shedding, they also demonstrated the presence of low  
levels of ds-sIL-6R in the RA joint (reviewed by (218). Furthermore, their experiments 
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showed the involvement of IL-6 transsignaling in a murine model of arthritis. While IL-6 KO 
(F2 mice C57Bl/6_129Sv) mice were resistant to the induction of AIA, reconstitution of the 
animals with IL-6 was only partially able to induce arthritis like symptoms. Reconstitution 
with Hyper-IL-6, a fusion protein consisting of human IL-6 and the human sIL-6R connected 
by a flexible polypeptide chain, however, led to joint inflammation at a level similar to wild 
type animals. In addition, they demonstrated that IL-6 transsignaling through Hyper-IL6 in 
AIA mice induces leukocyte recruitment through CCL2 expression. They further confirmed 
the important role of transsignaling in RA like disease in this animal model by showing that 
AIA in wild type mice could be blocked by the administration of sgp130 which binds to IL-
6/sIL-6 receptor complexes preventing IL-6 transsignaling (181).  
In summary, there is a considerable amount of evidence that IL-6 makes a strong contribution 
to the RA pathology, both via direct signaling and transsignaling. This is highlighted by the 
use of anti-IL-6R antibodies in clinical trials for RA (reviewed in (281)). Tocilizumab is an 
anti-IL-6R monoclonal antibody (206)  which recognizes IL-6R and its soluble form, sIL-6R 
(282). The administration of Tocilizumab causes an increase in IL-6 in serum due to the 
inability of cells to consume IL-6 as its receptor has been blocked in both forms, membrane 
bound and soluble form. Even though there is an increase in serum IL-6, its effects are 
efficiently blocked by the drug (283). Several clinical trials have been run internationally. 
Phase III clinical trials have resulted in around 40% ACR 50 responses. The use of 
Tocilizumab is safe and efficient, but there are other anti-cytokine drugs that work with a 
similar efficacy, such as anti-TNF-α. There is therefore the need to predict patient response to 
a particular drug in order to administer to each patient the drug that would be most efficient 
for him/her (reviewed by (281). 
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IL-6 is not the only survival factor for T cells in the RA joint. In 1999 our group reported that 
type I interferons rescue activated T cell blasts and converts them to the G0/G1 memory state 
resulting in inappropriate survival of T cells (139). T cells can also be potentially rescued 
from apoptosis by excess level of IL-15 found in the RA joint (112), IL-15 is an stimulatory 
cytokine for T cells that uses the gamma chain of the IL-2R to signal (284)  and upregulate 
genes that code for antiapoptotic proteins such as Bcl-2 (284). 
Continuing our studies, we investigated the regulation of CD126 and CD130 expression by 
CD4 T cells in SF and ST. In SF both CD126 and CD130 were found in very low levels. 
Since IL-6 has been reported to be able to downmodulate the expression of its receptor 
(reviewed by (51) and IL-6 is present at high concentration is the rheumatoid joint we had a 
very obvious candidate to be responsible for CD126 and CD130 low expression in SF. 
Indeed, our findings suggest that CD126 and CD130 expression on CD4 T cells from healthy 
donors can be downregulated following SF treatment and that this effect can be reversed by 
blocking IL-6 mediated signals in the SF. The next challenge was to find an explanation for 
the CD126 and CD130 phenotype seen on CD4 T cells from ST. CD130 expression on CD4 T 
cells in the perivascular areas of RA ST is high. First we decided to investigate if there is a 
possibility that CD130 is being induced locally, so we demonstrated that level of CD130 
mRNA present in ST CD4 T cells was higher compared to PB CD4 T cells. This does not 
provide comprehensive evidence for  CD130 being induced locally, but on the other hand if 
there had been low expression of CD130 mRNA, local induction of CD130 expression would 
have been very unlikely. It is, however, possible that CD130 expression is induced at other 
sites and that these cells selectively migrate to the inflammatory infiltrate in the inflamed 
synovium. We realize that the difference, though statistically significant is not very high.  
However, discrepancies between protein and mRNA data are frequent and can often be 
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explained by posttranslational regulatory processes. When comparing the CD130 expression 
between PB and ST T cells, we found no significant difference. More importantly, the 
functional difference between SF and ST T cells in their response to transsignaling suggests a 
potential biological role for CD130 expression in ST T cells. Also ST T cells, while they may 
express CD130 de novo are permanently in contact with IL-6/sIL-6R complexes which 
counterregulate the surface expression. We are therefore in a real –life situation looking at a 
dynamic equilibrium of mechanisms that continuously up and down regulate CD130. So the 
actual role of IL-10 may be to maintain the CD130 expression at the rate that counteracts loss 
from exposure to IL-6/IL-6R complex.. 
 To identify factors potentially involved in the upregulation of CD130, we investigated the 
effect of a large panel of cytokines found in the rheumatoid synovium on CD130 mRNA 
expression. We showed that CD4 T cells treated in vitro with IL-10 have higher levels of 
CD130 mRNA compared to untreated cells and cells treated with other cytokines. We also 
showed that IL-10 treatment triggers CD130 upregulation on CD4 T cells at the protein level 
and that the upregulation is titratable. This result was initially surprising as IL-10 is generally 
viewed as an anti-inflammatory cytokine. IL-10 can be produced by Th1, Th2, Th17, CD8 
positive T cells and some Tregs, monocytes, macrophages, dendritic cells, B cells, 
eosinophils, mast cells, keratinocytes, epithelial cells and some tumor cells. Data from our 
own research suggest that in the rheumatoid joint IL-10 is mainly produced by T cells and 
macrophages. (Personal communication, Yeo, L.). The two chains of the IL-10R are regulated 
independently. IL-10R2 is expressed by most cell types while IL-10R1 is expressed on most 
hematopoietic cells, epithelial cells and fibroblasts at very low levels but is upregulated upon 
many stimuli. The expression of the IL-10 receptor was demonstrated to be higher on CD4 
positive cells rather than CD8 T cells from PB of healthy controls by Schultz and coworkers 
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(285). If that is the case in an inflammatory setting CD4 T cells in the perivascular cuffs of 
RA ST are able to respond to IL-10 and upregulate of CD130. To date there is no information 
regarding IL-10 receptor expression by inflammatory cell populations in the rheumatoid 
synovium available.  IL-10 binds to IL-10R1 and this triggers the recruitment of IL-10R2 
which enables signal transduction. Following IL-10 binding Jak1 is recruited to IL-10R1 and 
Tyk2 is recruited to IL-10R2, they phosphorylate the intracytoplasmic tails of the receptor 
chains. These results in STAT3 recruitment subsequent phosphorylation and finally its 
homodimerization and release from the receptor. It then translocates into the nucleus where it 
binds to specific DNA sequences. It is interesting how two cytokines that activate the same 
signaling pathway like IL-6 and IL-10 can have such diverging effects. A possible 
explanation for this is that SOCS-3 inhibits STAT3 activated through the IL-6 receptor but 
not by IL-10, because SOCS3 does not bind to the IL-10R (89). 
IL-10 has various anti-inflammatory functions, it inhibits antigen presentation by 
downregulation of MHC class I molecules and co-stimulatory molecules CD80 and CD86 on 
DCs and Macrophages. Furthermore, it inhibits monocyte differentiation into DCs and DC 
maturation. IL-10 actions can result in inhibition of cytokine and chemokine production(286). 
However, IL-10 also has very important pro-inflammatory functions. IL-10 causes B cell 
activation and serves as a B cell survival factor; it also promotes class switching in B cells 
(reviewed in (87). It also exerts its proinflammatory effects on other cells types. NK cells 
proliferate and produce cytokines under the influence of IL-10 and IL-10 acts as a growth 
factor for CD8 positive T cells (reviewed by (79) in. Importantly, Cohen et al. demonstrated 
in 1997 that IL-10 can rescue T cells from apoptosis in vitro,  by Bcl-2 upregulation (287). If 
this finding was also confirmed in vivo and under inflammatory conditions IL-10 could well a 
role rescuing CD4 T cells from apoptosis in the context of RA directly by upregulating Bcl-2 
133 
 
in addition to the indirect pathway through triggering CD130 upregulation which in turn 
allows IL-6 anti-apoptotic signal to prevent cells death via transsignaling.  
The regulation of IL-6R and CD130 genes has been studied in several cell lines. In rat 
hepatocytes CD126 mRNA but not CD130 is upregulated by dexamethasone. IL-1 and IL-6 
can cause the downregulation of CD126 mRNA (288). In the brain, upregulation of  CD126 
and CD130 mRNA in selective areas of the brain was described following treatment with  
LPS or IL-1β(258). In line with our observation that  protein levels of CD126 and CD130 are 
regulated differently, Falus et al showed that the gene regulation of CD126 and CD130 can be 
independent (259).  
IL-6 signaling is not only regulated by the availability of its receptor, but also by SOCS 
molecules. SOCS molecules inhibit STAT-mediated signal transduction acting as negative 
feedback inhibitors (reviewed by (51). The expression of SOCS in RA is altered. SOCS1 is 
upregulated in PB T cells and SOCS3 is upregulated in PB monocytes from RA patients 
compared to controls. In SF macrophages the expression of SOCS 1 and 3 is high but SF T 
cells show no expression of SOCS (289). Therefore, SOCS deregulation in RA could 
contribute to excess IL-6 signaling that contributes to the overall inflammation.  
Since IL-6 and IL-10 both appear to be involved in the regulation of responsiveness to IL-6 
we decided to study the distribution of these two cytokines in the inflamed synovium. The 
expression of both of these cytokines has been described before in the rheumatoid joint 
(230,290) however we wanted to test how its localization within the tissue compares to IL-6 
receptor expression. We observed that IL-10 seems to be located mainly the perivascular cuff 
areas; this is exactly the location of high CD130 expression by CD4 T cells. We are not the 
first group to find a detrimental role for IL-10 in the context of RA. Huizinga and coworkers 
found an association between IL-10 promoter polymorphism -2849 that causes high IL-10 
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production and predicts more rapid development of joint damage in RA (184). Stonek F et al 
identified a further IL-10 promoter polymorphism, (-1082 G/A) in the IL-10 promoter which 
was associated with the production of autoantibodies such as RF in RA patients (291) and 
finally a possible mechanism triggering IL-10 production in the RA context was revealed by 
Xiao’s group in China, they found that heat protein 70, present in RA SF, triggers the 
production of IL-10 by fibroblast-like synoviocytes (292). Further evidence for a pathogenic 
role of IL-10 in RA derives from studies investigating recombinant IL-10 as a potential anti-
inflammatory treatment in RA.  There was no clear therapeutic benefit from the 
administration of rIL-10 in clinical trials. In a study conducted by Keystone et al RA patients 
were treated for 28 days with rIL-10 showing no adverse effects but also limited 
benefits(293). The use of rIL-10 as treatment of autoimmune disease remains controversial as 
it does not show benefits in various cases such as RA or Crohn’s disease it has, however, been 
shown to be beneficial in psoriasis (reviewed by (248)). At the time, given the known anti-
inflammatory properties of IL-10, the lack of efficiency was surprising. But if we consider the 
pro-inflammatory components of the effect of IL-10 on the immune system, it is possible that 
these counteract some of the anti-inflammatory properties. One of these proinflammatory 
properties may be the maintenance of sensitivity of T cell to IL-6 signalling by upregulation 
of CD126.  
To explore possible mechanisms that maintain IL-10 levels high in the rheumatoid joint, is 
worth thinking of IL-27. IL-27 has been demonstrated to induce IL-10 secretion by CD4 T 
cells and it has been shown to do so in combination with TGF-β too, in process dependent on 
STAT1 and STAT3 activation. In the other hand IL-6 combined with TGF-β also triggers IL-
10 secretion by CD4 T cells but in a STAT3 only dependent manner (294). This ability of IL-
27 and IL-6 to induce IL-10 would provide a possible mechanism for the high levels of IL-10 
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found in the rheumatoid joint. If the production of IL-10 in RA was dependent on IL-6 
signalling it would not be very high as we have shown the low expression of the IL-6R and 
the low responsiveness of CD4 T cells to IL-6 via direct signaling, but IL-27 could provide an 
alternative mechanism by with IL-10 production could be stimulated in CD4 T cells in the 
rheumatoid joint, IL-27 would stimulate CD4+_ T cells to produce IL-10 which in turn in our 
model would increase expression of CD130, making CD4 T cells responsive to IL-6 via 
transignaling and providing an extra mechanism to maintain IL-10 levels as IL-6 transignaling 
through CD130 could also result in more IL-10 production. And even if SOCS3 was activated 
to limit the extent of IL-6 signalling, IL-10 production induced by IL-6 and IL-10 dependent 
on STAT3 transcription factor would be reduced but IL-10 production induced by IL-27 
through STAT1 would not be affected. 
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 Figure 33. Model of CD130 expression and its consequences on T cells in the rheumatoid 
joint. This figure shows schematically the differential expression of CD130 on T cells in the 
different compartment of the joints. In addition shows a possible mechanism of CD130 
expression being regulated by IL-10 in the RA joint. 
In summary, as it can be seen in figure 33, our data suggest high expression of CD130 on 
CD4 T cells infiltrating the synovial tissue of the rheumatoid joint, which allows these cells to 
be signal by IL-6 though a process known as transsignaling. Our further investigations 
suggest that CD130 expression is triggered by the inflammatory micro-environment, possibly 
by the high presence of IL-10 in the perivascular infiltrate of the ST. We have shown that 
CD130 mRNA expression is likely to be locally induced and is not influenced by 
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transendothelial migration. All this suggests that transsignaling by IL-6/sIL-6R complexes 
may be an important survival and differentiation factor for T cells in the inflamed joint.  
 
In this study we have shown that there is no difference in the expression of CD25, CD69, 
CD71 and HLA-DR on T cells in early versus established arthritis. 
The expression of activation markers such as CD69, CD44 and HLA-DR on RA synovial T 
cells was previously shown by other groups (Cush and Lipsky 1230-38;Katschke, Jr. et al. 
1022-32). It has been difficult to demonstrate that T cells from the rheumatoid joint are 
producing cytokines, even after stimulation with anti-CD3 and anti-CD28 (Simon, Seipelt, 
and Sieper 8562-66;Dolhain et al. 1961-69), leading to controversial discussions of their 
relevance in inflammation. From our activation marker data we can only conclude that T cells 
are not different in activation status in early and established RA, therefore the hypothesis that 
T cells may have different roles in the different stages of RA is no supported. 
We also hypothesized that iNKT cells could be enriched in the very early stages of RA 
compared to established RA and therefore be a possible source SF cytokines found in very 
early RA, such as IL-4 and IL-13.. We showed that iNKT cells in PB are present in low 
numbers in all patients at similar levels to healthy controls. In SF iNKT cells are present in 
very low numbers in RA and early non RA at similar levels but in early RA there are virtually 
no iNKT cells. It is therefore unlikely that these cells make a major contribution to the 
cytokine profile found in the synovial fluid. 
Our results suggest that the numbers of iNKT cells in PB of patients with varying disease 
outcomes are very similar and also similar to healthy controls. Generally, in accordance with 
the literature, we found lower numbers of iNKT cells in SF compared to PB. Interestingly, the 
frequency of iNKT cells appears to be lower in SF of patients with VEA who eventually 
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progressed to RA. It is not easy to draw conclusions from these results because the actual 
number of cells analyzed is very low. . Linsen et al described a low frequency of iNKT cells 
in peripheral blood of patients with established RA (295) Our own observation of normal 
numbers of iNKT cells disagree with this finding. Possible explanation for this could be 
technical, the number of cells read in the flow cytometer, as so little iNKT cells are found in 
the blood we had to read a large number of cells to show a population of iNKT cells, another 
possible explanation may be the patients used for the study, which treatments they were on 
and how this treatments may affect the numbers of iNKT cells in PB. An additional 
explanation may be the characteristic of the control group used in the study; we compared our 
patients with age matched controls. It seems that iNKT cells may have a pathogenic role in 
RA as derived from the animal and human data, iNKT cells are indeed necessary to induce 
RA-like disease in animal models and seems to be present in the RA joint. Intriguingly, our 
data shows lower numbers of iNKT cells in very early stages of RA compared to later stages 
of disease. With the extremely low numbers of iNKT cells found in the SF of patients with 
VEA, it is impossible to assess their cytokine production. If indeed iNKT cells have a 
pathogenic role it may be possible that iNKT cell are recruited to the joint early in RA, are 
activated, secrete cytokines and undergo apoptosis after stimulation and even though they 
could contribute to the disease they are no longer seen in the SF. On the other hand, if we 
hypothesize a protective role of iNKT cells in RA, lower levels of iNKT cells may support the 
progression of early inflammation of the joint to RA.  
The most logical conclusion to be drawn from the lack of iNKT cells in SF is that these T 
cells subset is never recruited therefore not present and a very unlikely source of cytokines. 
IL-4 and IL-13, both cytokines present in SF in very early RA may be synthesized by other 
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cells present in the rheumatoid joint. Activated CD4 positive T  cells may be a source of both 
IL-4 and IL-13, while CD8 T cells may be a source of IL-13.  
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Figure 34. T cells in the RA joint. 
In summary,  we studied the presence of T cells subsets and T cells activation in different 
stages of RA, finding no significant differences in T cell subset presence or T cell activation 
status in early and late RA. Not supporting a different role for T cells in the different stages of 
RA. We also studied a possible mechanism contributing to T cell viability in RA; finding that 
high expression of CD130 on T cell in the rheumatoid joint caused by the local 
microenvironment may facilitate IL-6 transignaling and therefore T cell survival.  
The IL-6 data highlights the importance of IL-6 and T cells in RA and it gives IL-10 a 
possible pro-inflammatory role in the context of RA. These data suggests to me that 
interfering with IL-6 may be a powerful tool for treatment but it is not enough to target IL-6 
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direct signaling but also IL-6 transsignaling through CD130, in fact selective targeting to 
block IL-6 transsignaling only may have added benefits, it seems that there is not a lot of IL-6 
direct signaling taking place in the tissue and that many of the detrimental effects of IL-6 are 
mediated via transignalling. The added benefit for patients would be that IL-6 siganling would 
still be available to help fighting immune challenges through the acute phase response 
mediated by IL-6.  . In addition the role of IL-10 should be looked at as the presence of IL-10 
in the joint may not have any anti-inflammatory properties at all, in fact it may have a 
pathological role. As RA is such a multifactorial disease, in the sense that many factors are 
present contributing to the disease I think treatment should be equally aimed to several 
factors, targeting IL-6 or T cells or TNF separately may only lead to some improvement in 
patients whereas targeting various factors at once could be more effective so a combination of 
treatments targeting different cells and cytokines could be an option, always taking into 
account the overall immunity of the patient and not compromising his/her defense 
mechanism. There is still a long way to go and we have only made a tiny contribution to the 
puzzle that is RA but hopefully this information would be useful in the future and will 
contribute to the understanding of the disease. 
 
 
 
 
 
 
 
 
141 
 
Future Work. 
To take the project forward it would be interesting to identify the source of IL-10 in the 
rheumatoid joint. This work is currently in progress in our team. IL-10 is part of a family of 
related cytokines, it will be intriguing to test whether other members of the IL-10 family of 
cytokines have similar effects on CD130 expression. It will be important to determine 
whether IL-10 can upregulate CD130 expression in other cell types. In this context 
particularly B Cells are interesting, as IL-10 is an important growth factor for these cells. So 
far we have focused our research on arthritis. However, in SLE high levels of IL-10 have been 
described in the serum. It would therefore be interesting to study whether this affects 
expression of CD130 in this disease. Furthermore the relation between IL-10 and CD130 
expression so far is only associative, there is no direct proof for a link in the rheumatoid 
synovium. This could either be tested in animal models, by using Il-10 deficient mice or by 
using blocking anti IL-10 antibodies in cultures of cell suspensions derive from synovial 
tissue. 
While the work on activation markers and iNKT cells in very early arthritis currently does not 
appear to be a very promising line to pursue, we are now investigating the cytokine profiles of 
sorted immune cell populations in early and established RA using quantitative PCR on low 
density arrays. 
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Appendix 1: List of patients used for the T cell activation and iNKT studies 
 
Patient Age Gender Symptom 
Duration 
CCP CRP RF Medication Diagnosis 
1 58 F 12 weeks negative 21 Negative Indomethacin PA 
2 66 F 10 weeks negative 30 Negative Etoricoxib RA  
3 75 F 5 months NA 10 positive Diclofenac RA  
4 41 F 6 weeks positive 8 Positive Diclofenac RA 
5 41 F 6 weeks positive  8 Positive Diclofenac RA 
6 66 F NA NA NA NA Mtx RA 
7 59 F >10 years NA 111 Positive Etanercept RA 
8 41 F 10 weeks negative 0 Negative Ibuprofen RA 
9 44 M 5 weeks negative 12 Negative Celecoxib SLRA 
10 72 F >10 years NA 33 Positive Etanercept RA 
11 33 F 4 weeks Negative 0 Negative None SLUA 
12 64 F 7 weeks positive 34 Negative Arthrotec RA 
13 75 F NA NA NA Negative Mtx RA 
14 63 M 10 weeks Negative 44 Negative Prednisolone RA 
15 75 F 8 years NA 30 Positive None RA 
16 59 M 8 months Positive 11 Positive Mtx RA 
17 51 F 2 years Positive NA NA Naproxen RA 
18 66 F 5 months NA 36 Positive Etodolac RA 
19 33 F 2 years NA 21 Positive Naproxen RA 
20 77 M 7 weeks Negative 38 Negative Etoricoxib RA (self-
limiting) 
21 41 F 7 weeks Negative 0 Negative None Unknown 
22 58 F 7 years NA 88 Positive Mtx, ssa arthrotec RA 
23 73 M 5 years NA NA NA None RA 
24 69 M NA NA NA Positive NA RA 
25 40 M 1 year NA NA NA Mtx RA 
26 68 F 12 weeks Positive 77 Negative Diclofenac RA 
27 26 F 12 weeks Positive 20 Negative Arthrotec RA 
28 60 M 10 weeks Positive 63 Positive Diclofenac RA 
29 66 M 4 weeks NA 102 NA Naproxen Gout, OA 
30 72 F 19 years Positive NA Negative Mtx, ssa RA 
31 68 M 11 weeks Positive 6 Positive Ibuprofen RA 
32 71 F 30 years NA NA Positive Meloxicam, adalimumab RA 
33 23 F 8 weeks Negative 35 Negative Ibuprofen PUA 
34 72 F 19 years Positive NA Negative Mtx, ssa RA 
35 53 F 30 years NA NA Positive Hydroxychloroquine RA 
36 68 F 8 weeks Positive 15 Positive Ibuprofen RA 
37 23 F 11 weeks Negative 7 Negative Ibuprofen PUA 
38 45 M 6 months NA NA NA Mtx RA 
39 36 F 6 weeks Negative 5 Negative Etoricoxib PUA 
40 47 M NA NA NA NA Allopurinol, prednisolone Gout 
41 70 M 11 weeks Negative 79 Negative Ibuprofen RA 
42 38 F 8 weeks Negative 0 Negative Diclofenac SLUA 
43  M NA NA NA NA NA NA 
44 42 F 20 years Negative NA Negative Gold, prednisolone RA 
45 36 F NA NA 31 NA Mtx, leflunomide RA 
46 39 F 4 weeks Negative 34 Negative None Persistent 
SLE 
47 79 M NA NA NA NA Prednisolone, mtx RA 
48 18 F 12 weeks Negative 26 Negative Etodolac Persistent 
SLE 
49 64 F 5 weeks Positive 71 Positive Etoricoxib RA 
50 46 M 3 weeks Negative 38 Negative  None Reactive 
arthritis 
51 49 F 9 years NA NA Positive Diclofenac, adalimumab, 
leflunomide 
RA 
52 77 M 7 years Positive 45 Positive Azathioprine RA 
53 63 F 13 weeks Positive 43 Positive Etoricoxib RA 
54 39 M 4 years Positive 26 Positive Prednisolone, etanercept RA 
55 47 F 3 weeks Negative 228 Negative Diclofenac Sarcoid 
56 36 M 3 weeks Negative 0 Negative Ibuprofen SLUA 
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57 50 M 4 weeks Positive 26 Positive Diclofenac RA 
58 72 F 4 months Positive 91 Positive Prednisolone RA 
59 23 M 3 weeks Negative 0 Negative Ibuprofen Persistent 
PA 
60 49 M 1 year Positive 10 Positive Mtx, ssz RA 
61 56 F 4 years Positive 9 Positive Nabumetone, 
prednisolone, 
adalimumab, leflunomide 
RA 
62 63 F 11 weeks Negative 27 Negative Doclofenac NA 
63 50 F 5 weeks Positive 77 Positive NA RA 
64 40 M 5 years Positive 35 Positive Prednisolone, etanercept RA 
65 64 M 6 weeks Negative 15 Negative None SLUA 
66 75 F NA Positive 77 Positive Adalimumab, 
prednisolone 
RA 
67 56 F NA Positive 3 Positive NA RA 
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Appendix 2: list of patients used for the CD130 studies 
 
Patient Age Gender RF medication Diagnosis 
1 72 F NA Sulphasalazine RA 
2 74 F Positive None RA 
3 69 F Positive Sulphasalazine RA 
4 71 F NA Mtx RA 
5 71 F NA NA RA 
6 61 F Positive NA RA 
7 57 F Positive MTX RA 
8 57 F Positive None RA 
9 43 F Positive None RA 
10 36 F Positive Mtx, infliximab RA 
11 76 M NA Pred RA 
12 72 M NA None RA 
13 76 M NA Pred RA 
14 73 F NA Azathioprine RA 
15 62 F NA Pred RA 
16 62 F NA NA OA 
17 77 M Positive Nabumetone 
leflunomide 
RA 
18 73 M NA None RA 
19 53 F Positive Hydroxychloroquine RA 
20     RA 
21 38 M Positive Prednisolone, 
etanercept 
RA 
22 67 F Positive Etanercept, mtx RA 
23 66 M Positive Mtx RA 
24 70 F Positive Mtx RA 
25 53 F Negative Meloxicam, 
sulfasalazine 
RA 
26 52 M Positive Mtx, ssa, ohchl, 
pred 10, diclofenac 
RA 
27 57 F Positive Mtx, ssa, arthrotec RA 
28 58 F Positive Mtx, ssa, arthrotec RA 
29 49 M Positive None RA 
30 77 M Positive Azathioprine RA 
31 NA F NA NA RA 
32 39 M Positive Prednisolone, 
etanercept 
RA 
33 19 F Positive ibuprofen RA 
34 60 M Positive Doclofenac RA 
35 82 M Positive Arthrotec RA 
36 79 M NA Prednisolone, mtx RA 
37 36 F NA Mtx, leflunomide RA 
38 40 F Positive Doclofenac, 
adalimumab, 
leflunomide 
RA 
39 19 F Positive Ibuprofen RA 
40 73 F Positive Prednisolone RA 
41 33 F Positive Naproxen RA 
42 71 F Positive NA RA 
43 67 F Positive Etanercept, mtx RA 
44 78 F Positive Sulphasalazine RA 
45 NA F Negative None Psoriatic Arthritis 
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